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ABSTRACT 
 
 A targeted recombination system was developed for MHV-1 by generation of a 
Donor plasmid that consisted of sequences consisting of the first 448 nucleotides of the 
MHV-1 genome fused to sequences from codon 28 in the HE gene through the 3’UTR to 
the poly(A) tail.  The Donor plasmid was transcribed in vitro and transfected into FCWF 
cells that had been infected with a felinized MHV-1 recombinant virus.  Recombinant 
viruses were selected by overlaying infected/transfected FCWF cells onto murine DBT 
cells and monitoring for syncytia formation and cell death.  Recombinant viruses were 
plaque purified and expanded in murine cells.  Several recombinant viruses that were not 
significantly different from MHV-1 in tissue culture were isolated, but none were 
pneumopathogenic in the A/J mouse.  During the generation of multiple wild type 
MHV-1 stocks for mouse studies we discovered that MHV-1 rapidly lost 
pnuemopathogenicity during passage in DBT cells.  This finding demonstrated that 
targeted recombination may not be a viable method of genetic manipulation of MHV-1 
because the multiple passages in cell culture required to generate viruses by targeted 
recombination may cause loss of virulence.  Using Next-Generation sequencing 
technology a virulent and non-virulent MHV-1 passage were sequenced, and two 
potential mutations that are present in the subpopulation of virulent viruses were 
identified that may contribute to pneumopathogenicity: nsp13 C17015A and ns4 
G28454A. 
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We are developing an infectious cDNA clone using in vitro assembly of MHV-1 
cDNA fragments.  The fragments are flanked by type II restriction enzymes which, when 
digested liberate cDNA fragments that only contain MHV-1 genetic sequence and can be 
ligated together.  By housing portions of the MHV-1 genome in low-copy plasmids we 
were able to create a system that is easily maintained in bacteria and easily manipulated 
by restriction digestion or site-directed mutagenesis.  This infectious clone will be used 
to determine if the mutations that were discovered during the sequencing of the MHV-1 
pneumovirulent virus are sufficient and able to generate a pnueumopathogenic virus.  
The infectious clone will also be used to determine the role, if any, of ns2 in an MHV-1 
infection of lungs.   
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NOMENCLATURE 
 
SARS-CoV Severe Acute Respiratory Syndrome Coronavirus 
MHV-1 Murine Hepatitis Virus Strain 1 
MHV Murine Hepatitis Virus 
fMHV-1 recombinant MHV-1 virus expressing the Feline Infectious  
 Peritonitis Virus spike 
S Spike 
E Envelope 
HE Hemagglutinin Esterase 
M Membrane 
N Nucleocapsid 
P Passage 
LD50 Lethal dose, 50% 
pfu plaque forming units 
BL Biosaftey Level  
DBT Delayed brain tumor, cell line, mouse 
FCWF Felis catus whole fetus, cell line, cat 
L2 Lung, cell line, rat 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
INTRODUCTION 
Severe acute respiratory syndrome coronavirus (SARS-CoV) is a novel human 
coronavirus that caused the first major pandemic of the new millennium in 2002-2003(6, 
31, 56, 189).  Bats have been a source of a number of emerging zoonotic diseases, 
including Nipha and Hindra (51, 159).  The animal source of the novel human SARS-
CoV is thought to be Chinese horseshoe bats (80, 159).  It is believed that a bat 
coronavirus had adapted to infect civet cats and from civet cats was able to adapt to 
infect humans (80, 85, 159).  The receptor utilized by these SARS-like coronaviruses 
was shown to be angiotensin converting enzyme 2 (ACE2) (87).  Until the 2003 SARS-
CoV pandemic there was little urgency to study coronavirus-related human disease, 
because the disease in humans was usually a self-limiting upper respiratory infection (1, 
76, 98).  The SARS-CoV pandemic spurred a search for additional human coronaviruses 
and several new human respiratory coronaviruses, HKU1 and NL63 were discovered (1, 
88, 118, 187). These viruses, as well as previously known human coronaviruses (HCoV) 
OC43 and HCoV-229E were found to cause significant human respiratory disease in the 
elderly and in infants (1, 15, 19, 98, 118, 187).    A study done in Beijing, published in 
2013, showed that infection with four different human coronaviruses takes place during 
childhood (187). 
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Originally coronaviruses were thought to be limited to individual species and a 
narrow organ tropism in a given species (75, 85, 178).  The spike protein binds to its 
cognate receptor and initiates viral entry into a host cell.  Spike is a very strong 
determinant of tissue and species tropism.  There are also viral accessory genes that are 
thought to aid in viral replication in target species and tissues.  The spike protein and 
specific accessory genes were both thought to contribute to the limited the host-range of 
coronaviruses.  Since the SARS-CoV outbreak, and the resulting population studies, it 
has been postulated that these cross-species events occur more often than originally 
hypothesized (121).  The adaptation of SARS-CoV from bat to civet to human only 
required four amino acid mutation changes that resulted in a drastically increased 
binding affinity of the receptor binding domain from a human isolate for human ACE2, 
up 1000-fold from the original binding affinity of the receptor binding domain from a 
civet isolate of SARS-CoV (86).  So while spike and accessory genes can be host 
limiting, they are also capable of rapidly developing mutations that allow the virus to 
thrive in a different host.   
The more recent 2012 emergence of the Middle East respiratory syndrome 
coronavirus show a continuing need for animal models of severe coronavirus disease (5, 
97).     There are two overarching approaches to model penumopathogenesis: the direct 
contributions of the virus and the response of the host immune system.  It is the current 
opinion that the severity of the acute respiratory disease (ARD) in some SARS-CoV 
patients is, in large part, due to the immune response of the individual patient more than 
any predominant contribution of the virus (40, 110).  Herein is a review the genetic 
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methods that are available to study viral contributions to disease, the animal models that 
can be used in SARS-CoV infection, the ability of the animal model to mimic human 
disease, and the viruses that are used in studying SARS-CoV biology and disease 
pathogenesis.     
REVIEW OF CORONAVIRUS BIOLOGY 
Coronaviruses are a member of the family Coronaviridae in the order 
Nidovirales.  The Coronaviridae are further subdivided into the Torovirinae and 
Coronavirinae subfamilies.  The Coronavirinae in turn are split into four genera (alpha, 
beta, gamma, and delta coronaviruses) based on phylogenetic classification (72).  SARS-
CoV has been phylogenetically classified as a betacoronavirus (72, 155).  Other related 
betacoronaviruses include mouse hepatitis virus strain-1 (MHV-1), mouse hepatitis virus 
strain A59 (MHV-A59), and mouse hepatitis virus strain JHM (MHV-JHM).  Human 
coronaviruses CoV-HKU1 and HCoV–OC43 are also classified as betacoronaviruses.   
Coronaviruses are enveloped RNA viruses with genomes that range in size from 
28 to 31 kb in length.  The genomes have a 5’ cap and a 3’ polyadenosine tail and 
contain untranslated regions at the 5’ and 3’ ends of the genome which have been shown 
to contain secondary structures that are important for virus replication and growth in cell 
culture (47, 67, 140, 168).  The 5’ two-thirds of the genome encodes two open reading 
frames (ORF): ORF1a and ORF1b.  These have a relatively short region of overlap 
which contains a ribosomal frame shift signal that results in the translation of two large 
polyproteins called ORF1a and ORF1a/b.  ORF1a is encoded in the first third of the 
genome and ORF1a/b is encoded by the first two-thirds of the genome.  Once translated 
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these polyproteins are cleaved into 15-16 nonstructural proteins (nsps1-nsp16) (19). 
These ORF1a/b derived proteins are responsible for RNA replication and transcription.  
However, while the cleavage sites and number of proteins are consistent among 
coronaviruses, and the proteins are generally well conserved, especially in ORF1b, the 
actual genes in this region also contain unique regions that are not conserved.  Because 
of their limited coding capacity, viruses, even large viruses like coronaviruses, encode 
proteins that have more than one functional domain, though only some of the functional 
domains are conserved between viral groups (43, 56, 68, 104).  In general coronaviruses 
have, after the ORF1a/b region, a series of virus species-specific genes dispersed 
amongst genes that code for structural proteins.  All coronaviruses encode the spike 
protein (S), envelope protein (E), membrane protein (M), and nucleocapsid protein (N) 
in that order going from the 5’ to 3’ direction of the genome, and this is followed by an 
untranslated region that is functionally important (48, 90, 161).  Many 
betacoronaviruses, including two pathogenic human coronaviruses, CoV-HKU1 and 
HCoV-OC43, contain a hemagglutinin esterase gene (HE) but SARS-CoV and other 
SARS-like-CoV do not.  Encoded with the S-E-M-N are strain-specific genes, also 
referred to as accessory genes, which greatly vary between coronaviruses.        
 It is generally accepted that the SARS-CoV of 2002-03 pandemic was the result 
of host switching from bat to civet cat to human due to mutations in the spike protein.  
The actual genetic history of SARS-CoV is less clear on the events that lead to the 
pandemic because genomic analysis demonstrates that SARS-CoV have a unique 
evolution consisting of both mutation and recombination events (141).  Early genomic 
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analysis showed that SARS-associated coronaviruses might have possessed a 
recombinant RNA dependent RNA polymerase that was derived from an avian 
coronavirus (121).  However, later studies seem to point towards bats as the likely 
source because bats have a high diversity of coronaviruses present in the population, and 
it is more likely that SARS-CoV was generated from the bat coronavirus lineage  (7, 80, 
122, 159).  There is also indication that the SARS-associated coronaviruses have been 
evolutionary independent for a period of time prior to the outbreak (64, 121). Also, while 
SARS-CoV is considered as a single entity, there are several studies that indicate that 
SARS-associated coronaviruses also maintain a quasispecies, which may indicate that 
the events leading up to and during the pandemic were not solely due to the host range 
changes that can be attributed to the spike protein, but rather to a complex interplay of 
different virus subspecies that allowed for the selection of a new human pathogen (64, 
141).  During the epidemic different quasispecies strains were being generated and had 
potential effects on patient health and survival (144).  Studies have demonstrated the 
presence of multiple quasispecies of SARS-CoV in a individual patient (142, 166).   The 
role of quasispecies in SARS-CoV is unclear, though intriguing.  Coronaviruses do have 
a mechanism to recognize and correct mutations that arise during genome replication, 
the nsp14 exonuclease.  The presence of this exonuclease lead to reasoning that assumed 
that coronaviruses did not utilize the mechanisms of quasispecies diversity to the extent 
that other RNA viruses did (32).  However, with the new data that supports quasispecies 
in SARS-CoV this idea may need to be reevaluated. To date there have been no studies 
reporting the clinical severity and outcome related to SARS-CoV quasispecies. 
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After a coronavirus enters the cell through receptor mediated endocytosis and 
fusion with the endosomal membrane or direct fusion of the viral envelope with the 
plasma membrane (33, 44, 88, 149, 158), the positive-stranded genome is translated into 
the ORF1a and ORF1a/b polyproteins (44).  These polyproteins are cleaved into 
individual nsps 1-16  by virally encoded protease activities: papain-like-protease 
domain(s) (PLP) and a 3C-like protease (3CLpro), with the PLP domain(s) mediating the 
nsp1-nsp3 cleavages, with remaining proteolysis steps being mediated by the 3CLpro 
(20, 48, 96, 112).  Once the viral polymerase and other non-structural proteins required 
for viral RNA synthesis are translated and subsequently cleaved from the polyprotein, 
transcription of the genome and of the subgenomic fragments begins. Viruses of the 
order Nidovirales have a distinct replication strategy in that ORFs 3’ to ORFs1a/b 
representing the 3’ one-third of the genome are expressed via multiple subgenomic viral 
mRNAs.  These subgenomic mRNAs make up a 3’coterminal nested set.  Coronaviruses 
have a unique transcription regulatory sequence (TRS) that is present in the 5’ region of 
the genome, called the leader TRS,  and at other locations throughout the genome, 
usually directly upstream of a coding region outside the ORF genes and these are called 
body TRS (34, 188).  It is believed that during negative strand synthesis the leader TRS 
is brought around to the 3’ end of the genome and forms a 5’-3’complex with the RNA 
dependent RNA polymerase.  As the polymerase generates the negative strand the 
polymerase passes a body TRS, which can now base-pair with the leader TRS and can 
allow for the polymerase to switch templates.  The polymerase moving from the TRS to 
the 5’ end is what generates the coterminal ends of the subgenomic negative RNA.  The 
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negative RNA is then transcribed into a positive strand to be used for protein synthesis.   
The number of mRNAs (including the genome RNA) synthesized varies from virus to 
virus and ranges from 7-9.   The transcription of each subgenomic mRNA is not equal, 
with the molar ratios of the mRNAs generally decreasing as their size increases (115).   
All proteins encoded 3’ to ORF1a/b are under a unique transcription regulatory sequence 
(TRS) that is just upstream of the coding sequence of the protein.  The TRS is critical to 
the generation of the subgenonic mRNAs and TRS sequences are unique to different 
coronavirus species (132, 188). The relative amount of mRNA affects the amount of 
translated protein.  The proteins are translated and the virus is assembled in the 
endoplasmic reticulum-Golgi intermediate compartment and a complete viral particle 
buds from the endoplasmic reticulum into the trans-Golgi network (94, 169).  Virus 
particles, or in some cases virus-like particles that are have structural proteins but no 
genomic RNA, are transported to the cell membrane and released.  Because 
coronaviruses bud through the ER and trans-Golgi, some of the S protein is able to be 
transported to the plasma membrane independently, and if the S protein has the ability to 
fuse at neutral pH (not all coronavirus S proteins have this property) some coronaviruses 
are capable of forming syncytia, or large multinucleated cells.  The size and amount of 
syncytium formation varies by virus strain and syncytium formation and size is 
considered to be a part of the viral life cycle and to contribute to viral spread and 
pathogenesis (169).   
Coronaviruses overwhelm an infected cell by promoting the degradation of the 
host cell’s mRNA (66).  When most of the host cell’s mRNA is degraded the only 
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mRNA available to translation is viral, so viral proteins will be primarily produced.  
Coronavirus nsp1 is able to reduce host mRNA expression without effecting the 28 and 
16S ribosomal RNA levels.  Studies have shown a difference in the modification of cell 
cycle genes between young and aged animals (6, 138).  Viruses control the cell cycle so 
that they can utilize the cellular machinery and products that are usually present in the 
synthesis phase of the cell cycle which contributes to pathogenesis and can create 
difference in disease out come in different ages of hosts (6, 124, 128, 137, 138). This is 
possibly due to the idea that in older individuals more cells have reached a senescence 
phase and do not have large numbers of cells actively undergoing mitosis. 
SARS-CoV HUMAN DISEASE AND PATHOGENESIS 
Early cases of SARS-CoV are believed to have originated in southern China 
where, in November of 2002, there was an unusual epidemic of a severe pnueumonia in 
Foshan, Guangdog (55, 180).  The Foshan index case infected his wife and three other 
relatives, but not his children or any hospital staff.  The early phase of the SARS-CoV 
outbreak began with the Heyuan index case, a chef working in the city of Shenzhen, 
began to have fever and flu-like symptoms on December 10th of 2002 and was 
hospitalized in Heyuan on December 15th (180).   During his stay he infected seven 
hospical staff members and one patient, which was the first recognized case of SARS-
related hospital infection.  This disease was, at the time, of an unknown aetiology and 
would prove to have a high rate of transmission to healthcare workers in China (55).  In 
February of 2003 a 64 year old nephrologist from southern China visiting Hong Kong 
and he is believed to have been the index case of Hong Kong and source of infection that 
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lead to subsequent SARS-CoV outbreaks in Hong Kong, Vietnam, Singapore, and 
Canada, which started the pandemic middle phase of the outbreak (30, 55, 79).  During 
his stay at least 16 hotel guests and visitors were infected and within weeks the atypical 
pneumonia had spread an affected more than 8000 people in 25 countries and regions 
across five continents.   
In 2003 the epidemiologically linked patients from Hong Kong that presented 
with a fever, rigor, dry cough, dyspnea, malaise, headache, hypoxia, and crackles and 
percussion dullness in physical exams of the chest (150).  Serial chest radiographs 
showed a progressive air-space disease.  Two patients died of progressive respiratory 
failure that was a result of diffuse alveolar damage.  This disease was named Severe 
Acute Respiratory Syndrome (SARS) and appeared to be of infectious origin.  This 
disease had already been reported to the World Health Organization in Guangdong 
Province, China in late 2002 (14, 180, 189).  Later in 2003 the infectious agent was 
shown, through electron-microscopy and RT-PCR sequence analysis, to be a novel 
coronavirus (31, 109).   
Clinical Features and Histology 
Though SARS-like viruses are capable of infecting individuals of all ages, 
mortality due to disease is highest in the elderly.  Patients present with a fever and rigor 
with a nonproductive cough, malaise and headache (37, 150).  Chest crackles and 
dullness on percussion were also detected in most patients upon physical examination of 
the chest.  Most patients have abnormal chest radiographs on presentation with the 
primary abnormality in the initial radiograph showing air-space shadowing that included 
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ground glass opacities, focal consolidation, or patchy consolidation.  Opacities were 
predominant in the lower lung zones in most patients, though some patients did show 
opacities in the upper zones.  In general, air-space opacities increased in size, extent, and 
severity within the first 10 days.  The predominant abnormalities that were found on CT 
scans of patients were subpleural focal consolidation with air bronchograms and ground 
glass opacities that occurred mostly, but not exclusively, in the posterior aspects of the 
lower lobes.    While the mortality rate for SARS-CoV infection is, overall, only around 
10%, that rate rises to 50% for those patiens over 60 years of age (14, 124, 150) 
Severe clinical worsening with the development of dyspnea occurs about 5 days 
after the onset of illness, coincident with the development of an antibody response to 
infection and a decrease in viral titer and replication (105).  In cases of severe disease of 
short duration, 10 days or less, the histopathologic changes in the lung include acute-
phase diffuse alveolar damage, edema, fibrin deposition, hyaline-membrane formation, 
and pnuemocyte proliferation (31, 36, 109).  Lungs of patients that succumbed to their 
disease after 10 days of illness displayed histopathologic lesions of organizing-phase 
diffuse-alveolar damage, type II pneumocyte hyperplasia, squamous metaplasia, 
multinucleated cells, and acute bronchopnuemonia. In all cases analyzed the diffuse-
alveolar damage was the primary pathology.  A three stage process in the lungs has been 
described with an initial inflammatory or exudative phase, a proliferative phase, and a 
final fibrotic phase (91).  Macrophage proliferation occurs in consolidated areas of the 
lung (106).  Haemophagocytosis in the lung and white-pulp atrophy in the spleen, has 
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been attributed to cytokine dysregulation that is reminiscent of fatal influenza subtypes 
H5N1 disease from 1997 (39, 161).    
SARS-CoV primarily targets the pneumocytes and macrophages, where 
pneumocytes are the initial site of infection and the macrophages take up the virus and 
disseminate virus throughout the lungs (42).  Once the pneumocytes are infected, 
macrophages will take up the virus and disseminate it throughout the lungs and, 
potentially, other organs.  A Toronto study analyzed fatal cases of SARS-CoV and found 
that there was often virus dissemination to other organs (36).  SARS-CoV was found in 
all patients’ lung tissue, in 73% of bowel samples, 69% of lymph node samples, 41% of 
liver samples, 40% of cardiac samples, 38% of kidney samples, and 12% of skeletal 
muscle samples.  The bowel had a high viral load, but had minimal histopathological 
changes.   There was a 100% correlation of patients having SARS-CoV in the liver and 
abnormal liver function tests antemortem.  Only 40% of patients with abnormal liver 
function had no SARS-CoV in the liver.  Patients secreted virus in nasopharyngeal 
aspirate and from feces for up to 21 days after disease onset (182).  The Toronto study 
found high viral loads in the gut and liver and moderate loads in the kidney, which is 
consistent with viral shedding patterns (36).  The length of time of post-infection viral 
shedding, up to 21 days, indicates a difficulty in clearing the virus, which is a common 
feature of murine coronavirus infection in mice (6, 45).   
Studying the innate immune response that is initiated in SARS-CoV infection is 
difficult because the human lung is a heterogenous mixture of cell types, each of which 
will respond differently to infection (135, 172).  Only some of those cell types express 
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the ACE2 receptor and are susceptible to infection by SARS-CoV.  A major effector in 
the pathogenesis of SARS-CoV is the role of ACE2 in lung injury.  In addition to its role 
as the receptor which allows SARS-CoV to infect its target cells, ACE 2 is thought to 
have a pneumoprotective role in lung injury. Intratracheal installation of recombinant 
Spike-Fc protein in mice resulted in decreased ACE2 expression and a worsening of acid 
induced lung injury (61).  It is thought that the down regulation of ACE2 receptor by 
Spike-Fc protein reduces the ability of the lungs to negatively regulate AngII signaling.  
In recombinant Spike-Fc protein treated lungs there is a significant increase in the 
amount of AngII present after an acid wash.  If the mice are treated with an AngII 
receptor blocker the increased severity of lung injury observed in mice after Spike-Fc 
treatment in the acid injury model is significantly decreased, but is not returned to 
control levels.  The pharmacological blockade of Ang II receptor AT1 also decreased the 
amount of pulmonary edema in the injured lung.  This study demonstrates that down-
regulation of the ACE2 receptor for SARS-CoV is capable of causing a worsening of 
lung injury independently of viral infection.   
SARS-CoV Cytokine/Chemokine Response 
IL-6 and IL-8 are highly expressed in SARS-CoV infected patients (150, 179) 
and also in patients with ARDS induced by other causes (128) (Table 1).  In this latter 
group of patients TNF-α, and IL-1β are also strongly induced (128).  SARS-CoV 
infected patients also have elevated levels of circulating IP-10, with high IP-10 being 
correlated with poor patient outcome (41).  There has been little to no detection of  
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Table 1. List of Cytokines/Chemokines elicited during a SARS-CoV infection of 
humans, cells, and animals1 
Cytokine/ 
Chemokine 
Function2 Increase or Decrease 
Human Cell line Animal 
Model 
IFN-β Antiviral properties No change No change ↑early 
TNF-α mainly secreted by macrophages,  
involved in the regulation of a wide spectrum 
of biological processes including cell 
proliferation, differentiation, apoptosis, lipid 
metabolism, and coagulation 
↑  ↑ 
TGF-β Multifunctional protein that controls 
proliferation, differentiation and other 
functions in many cell types 
↓   
IFN-γ produced by lymphocytes,  potent activator of 
macrophages 
 ↑  
IL-18/ 
IGIF 
cytokine that augments natural killer cell 
activity in spleen cells, and stimulates 
interferon gamma production in T-helper type 
I cells 
 ↑  
IL-6 functions in inflammation and the maturation 
of B cells, primarily produced at sites of 
inflammation 
↑end  ↑ 
IL-8 chemotactic factor that attracts neutrophils, 
basophils, and T-cells, but not monocytes; 
involved in neutrophil activation 
↓ 
↑progressive 
and end 
 ↑ 
NF-κB transcription regulator activated by various 
stimuli such as cytokines, oxidant-free 
radicals, ultraviolet irradiation, and bacterial 
or viral products  
↑late   
STAT signal transducer and transcription activator 
that mediates cellular responses to interferons, 
cytokines, and growth factors 
↑activation 
↓nuclear 
transport 
↑activation ↑activation 
 
Elk-1 functions as a transcription activator in MAPK 
signal transduction 
   
CCL-20 chemotactic factor that attracts lymphocytes 
and neutrophils, but not monocytes; involved 
in mucosal lymphoid tissues by attracting 
lymphocytes and dendritic cells towards 
epithelial cells. 
↑early   
IL-1α produced by monocytes and macrophages and 
released in response to cell injury, and thus 
induces apoptosis 
No change   
CXCL-10/ 
IP-10 
stimulation of monocytes, natural killer and T-
cell migration, and modulation of adhesion 
molecule expression 
↑   
CCL-2/ 
 
chemotactic activity for monocytes and  ↑   
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Table 1. continued 
 
1References Used: (22, 41, 42, 48, 65, 81, 128, 138, 172, 179, 182, 186) 
2Functions are adapted from entries in Gene Cards (http://www.genecards.org/) 
 
 
 
 
 
 
 
 
Cytokine/ 
Chemokine 
Function2 Increase or 
Decrease 
Cytokine/ 
Chemokine 
Cytokine/ 
Chemokine 
MCP-1 basophils but not for neutrophils or 
eosinophils. It has been implicated in the 
pathogenesis of diseases characterized by 
monocytic infiltrates. 
↑  ↑ 
CCL-5/ 
RANTES 
functions as a chemoattractant for blood 
monocytes, memory T helper cells and 
eosinophils; causes the release of histamine 
from basophils and activates eosinophils. 
↑  ↑ 
CXCL9/ 
MIG 
thought to be involved in T cell trafficking as 
a chemoattractant 
↑   
CCL-3 involved in the recruitment and activation of 
polymorphonuclear leukocytes 
↑   
IL-10 produced primarily by monocytes and to a 
lesser extent by lymphocytes; down-regulates 
the expression of Th1cytokines, MHC class II 
Ags, and costimulatory molecules on 
macrophages; enhances B cell survival, 
proliferation, and antibody production. 
↑convalescent  - 
IL-17 proinflammatory cytokine produced by 
activated T cells; regulates the activities of 
NF-κB and mitogen-activated protein kinases; 
can stimulate the expression of IL6 and 
cyclooxygenase-2 (PTGS2/COX-2), as well as 
enhance the production of nitric oxide (NO) 
  - 
IL-12 Acts as a growth factor for activated T and 
NK cells, enhance the lytic activity of 
NK/lymphokine-activated Killer cells, and 
stimulate the production of IFN-gamma by 
resting PBMC 
  ↑ 
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interferon early in SARS-CoV infection in patients (13, 148).  Coronaviruses are in 
general poor inducers of interferon relative to most other RNA viruses, and this has been 
attributed to the sequestering replication complexes containing dsRNA in double 
membrane vesicles to avoid detection by the host and activation of the interferon 
response (21, 183, 185).   For SARS-CoV a large number of proteins including ORF 3b, 
ORF6, ORF7, N, nsp1, and M proteins antagonize the IRF-3-STAT axis of the interferon 
pathway (48, 66, 143).  These proteins promote the degradation of cellular RNA and 
inhibit the formation of the TRAF3TANKTBLI/IKKKε complex (172).  SARS-CoV 
ORF6 protein also prevents STAT1 from being imported into the nucleus, but only in 
infected cells (39, 42).  Neighboring uninfected cells are still able to phosphorylate 
STAT1 and transport it into the nucleus, which leads to the eventual expression and 
accumulation of significant levels of interferon in some patients. 
In the Calu3 lung cell line NF-κB, STAT, and Elk-1 were persistently expressed 
starting 12 hours post infection (172).  CCL-20, IL-1A, IL-6, and IL-8 are the first group 
of cytokines activated in Calu3, but are not activated until 24 hours post infection.  The 
activation of IRF-7, which is a critical mediator of the antiviral effects of type 1 
interferons, was not observed until 48 hours post infection.  The consequence of this 
delayed activation of IRF-7 is that significant antiviral effect from type 1 interferon 
would not occur until 2-3 days post infection.     
Immune Response to SARS-CoV Infection 
 
Cells that are infected with SARS-CoV do not express IFN-β, creating an initial 
failure of the innate immune system to be able to respond to infection.  SARS-CoV 
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infection is known to, in vitro, result in inefficient activation of macrophages and 
dentritic cells (DC) (42). In the MA15 infected BALB/c mouse model of SARS-CoV 
infection alveolar cells have been shown to have a poor ability to activate T cells, which 
are needed for the adaptive immune response in coronavirus infection (181, 182).  In 
BALB/c mice the majority of virus specific T-cells did not produce IL-10 or IL-17 
(181).  When BALB/c mice were immunized to SARS-CoV by injection of DC that had 
been pre-coated with an immunogenic portion of the SARS-CoV spike protein then mice 
were able to generate specific, protective T-cells in the lungs and spleen.  However, 
during normal infection of mice, DC are not activated properly, so DC are unable to 
generate specific, protective T-cells that can protect in a primary SARS-CoV infection.  
Alveolar cells have been shown to suppress the ability of macrophages and DC to 
present antigens to induce adaptive immune responses (182). Consistent with the 
increased severity of SARS with increasing age in human patients depletion of alveolar 
macrophages in young mice had no effect on disease, but depletion of alveolar 
macrophages in aged mice protected these mice from otherwise lethal disease, 
suggesting that a dysregulation of macrophage responses to infection with aging 
contribute to severe disease (182).   
GENETIC APPROACHES TO STUDY CORONAVIRUS PATHOGENESIS 
Coronaviruses have been studied for over 60 years.  Throughout the years the 
methods of evaluating viruses have changed, and scientists are continually developing 
methods that allow us to rapidly evaluate viruses.  Some of the methods that are 
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available to evaluate the role of SARS-CoV in infection and disease are discussed 
below.  
Transgenic Animals 
The use of transgenic mice in studying coronaviruses is twofold: elimination of 
the need for host adapted viruses and abrogating elements of the host immune response 
to study changes in the pathology induced by infection and the role of these elements in 
pathogenesis.  Several labs have generated transgenic mice that express the human 
ACE2 receptor so that SARS-CoV could be studied without the requirement of virus 
adaptation to a murine host.  McCray et al generated a transgenic C57Bl/6 mouse that 
expresses the human ACE2 receptor (hACE2) under the control of the human 
cytokeratin 18 promoter which confers transgene expression in airway epithelial cells 
(but not in alveolar epithelia), as well as in epithelia of other internal organs  (3).  The 
transgenic mice expressed similar levels of mouse ACE2 as the non-transgenic 
counterparts in the lung, but in addition hACE2 was expressed in multiple organs, where 
the ACE2 receptor is not normally found, though this did not guarantee SARS-CoV 
infection as the virus was not detected in the liver, kidney, or ileum at either 2 or 4 days 
post infection.  Furthermore, the level of hACE2 in the brain was increased as well as in 
other tissues that normally express ACE2.  These mice suffered a lethal disease, with 
100% mortality by day 7 in both strains when infected with 2.3x104 PFU.  Tseng et al 
(151) generated two lines of transgenic mice, AC70 and AC63, which both expressed 
hACE2 ubiquitously, but AC70 expressed hACE2 at a higher level.  Because of this 
AC70 mice developed clinical illness regardless of the route of inoculation (intranasal or 
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intraperitoneal) and died uniformly within 8 days if infection; whereas AC63 mice 
developed clinical symptoms but eventually recovered from the infection.  These mice 
also had extensive infection of the CNS during infection.  However, researchers noted 
that not all hACE2 expressing cells in the CNS were susceptible to SARS-CoV 
infection, finding that they were unable to detect SARS-CoV antigen in endothelial cells 
of the brain despite their abundant expression of ACE2.  While both models may seem 
extreme in the over-expressing of hACE2 throughout the mouse it is important to realize 
that SARS-CoV has been found in multiple organ sites in human patients, and that 
multiorgan involvement is associated with fatal cases of SARS-CoV infection (36, 50).  
The transgenic hACE2 mice that have been developed to date result in lethal disease 
when infected with wild type SARS-CoV but in addition to pulmonary infection, a 
severe encephalitis which is not a feature of SARS in humans likely limits their 
usefulness to studies of antiviral agents and vaccines on SARS-CoV infection.   
Knock-out mice have been successfully used in evaluating the roles of the 
interferon system in controlling coronavirus infection (40, 119, 135, 162).  IFNAR-/- 
mice, mice that have the IFN receptor knocked out, have been used to demonstrate that 
IFN signaling is important in control of virus replication and dissemination as well as 
protection of pulmonary disease (119, 120).  These mice also demonstrate that there are 
secondary mechanisms by which the cell can signal genes that are predominantly 
regulated by IFN, though these mechanisms were not discussed.  Experiments with mice 
that have had the ACE2 receptor knocked out have confirmed that ACE2 is important in 
the infection of SARS-CoV, as animals not expressing ACE2 had a 105 fold lower titer 
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in the lungs than wild type animals (60).  STAT1-/- mice are resistant to the antiviral 
effects of IFN and show worsening of pulmonary disease and an increase of viral 
replication in the lungs (54).  These animals also have a systemic spread of virus to the 
liver and spleen. 
Reverse Genetic Systems For Studying Coronaviruses 
Adaptation mutations are useful in identifying genes that are species unique, but 
do not test the effect of other genes that may be able to effect pathogenesis regardless of 
species.  To investigate a gene’s individual contribution a method to make 
predetermined and targeted changes in select genes is required.  There are two options 
for manipulating coronavirus genomes: targeted recombination and a complete reverse 
genetic system. 
Targeted recombination 
Targeted recombination takes advantage of the high natural recombination rate of 
coronaviruses (89).  During normal coronavirus replication the coronavirus RNA 
dependent RNA polymerase (RdRp) employs a mechanism akin to template switching 
during minus strand RNA synthesis to accomplish leader-body joining and generate 
templates for subgenomic mRNA synthesis (115, 132, 188),  and this property of the 
RdRp is thought to contribute to the high recombination rate through template switching 
(34).  Targeted recombination takes  advantage of this natural event, in vitro transcribed 
RNA is electroporated into an infected cell and recombinant virus is generated (38, 53, 
84, 93).  Recombinant viruses need to be selected from non-recombinants and the 
selection methods employed have limited this method to manipulating only the 3’ most 
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third of the genome.  It is possible for there to be multiple template switching events, so 
the distance from the original template switch site is important to consider when using 
this method.  The first targeted recombination system used a temperature sensitive trait 
to select and screen for template switching between the original temperature sensitive 
virus containing a mutation in the N gene and the new recombinant virus that had lost 
the temperature sensitive phenotype due to recombination (73).  A later experiment 
optimized the targeted recombination method by substituting the spike protein of MHV-
A59 with the spike protein from Feline Infectious Peritonitis virus on the donor RNA 
(75).  This allowed recombination events to be selected based on the host range of the 
spike protein: mouse or feline, and selected for template switching events that were 5’ to 
the S gene rather than recombination events that were 3’ to the temperature sensitive 
mutation in N.  The host range selection was much more stringent: a recombinant MHV 
that expressed the FIPV spike would only grow on feline cells, the non-recombinant 
MHV would not.  The resulting recombinant felinized virus expressing FIPV S was then 
used as an acceptor using transcripts of donor RNAs containing the original MHV spike 
and any additional mutations engineered into the S gene or sequences 3’ of the S gene.  
Any viruses that underwent template switching to the donor RNA would now have the 
MHV spike and can be selected by their ability grow on mouse cells, whereas the 
felinized MHV acceptor virus could not.  This efficient selection based on host range 
facilitates the identification and culturing of recombinant viruses.  
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Complete reverse genetic systems 
In order to evaluate the remaining genes in the coronavirus genome complete 
reverse genetic systems were developed.  There are three different systems that can be 
used for coronaviruses: a systematic assembly of 7 plasmids (134, 175), an infectious 
cDNA clone that houses the genome in a bacterial artificial chromosome (BAC) (4, 
114), and a recombinant vaccinia vector (146).  Both the BAC and vaccinia vector are 
able to house the entire coronavirus genome as a single piece.  Because the viral genome 
is housed as a single piece unique restriction sites may need to be introduced into the 
genome in order to facilitate assembly of the clone as well as to facilitate later 
manipulations of the genome, though this is not always necessary (4, 114).  BACs can be 
stably maintained for over 200 passages (4).  Vaccinia vectors are classically known for 
their stability (77).  One advantage of these systems is a consistently higher amount of 
whole genomic cDNA that can be prepared for in vitro transcription since there is no 
stepwise ligation of cDNA fragments, and loss during this process, to generate the 
genomic cDNA.  The BAC system also can be designed with a CMV promoter and thus 
the BAC can be transfected into cells and generate recombinant virus without in vitro 
transcription.  The vaccinia model has been able to successfully generate a reverse 
genetic system where the 7 plasmid system failed (146). A drawback to these systems is 
that having the entire genome housed in one vector makes generating mutant viruses 
more challenging than when the genome is subdivided into multiple plasmids because 
the number of unique restriction sites is reduced.  
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The most widely used system is the 7 plasmid in vitro cDNA ligation system (19, 
23–26, Weiss lab personal comminuation).  The complete reverse genetic system is 
comprised of 7 plasmids that each contain a cDNA fragment corresponding to a portion 
of the genome (173–176).  The plasmids that contain the genomic fragment are digested 
with type IIS restriction enzymes that have been engineered to flank the genomic cDNA 
insert.  Enzyme digestion can then liberate the cDNA genome fragment without altering 
the viral genome sequence.  These cDNA fragments are ligated together and in vitro 
transcribed to form a viral genome RNA that can now be transfected into cells with the 
N gene, either independently expressed or as transcribed RNA) and a recombinant virus 
can be generated.  This system requires more in vitro manipulation to generate a full 
length cDNA that can be used for transcription.  However, the maintenance of the 
genome in multiple fragments facilitates the manipulation of the genome.   
SARS-COV MODELS OF DISEASE 
A recent paper comparing transcriptional profiling in human systemic 
inflammatory diseases and the corresponding mouse models reported that transcriptional 
responses in murine models were a poor mimic of the responses in human disease (136).  
This study compared the transcriptional responses between humans and mice in large 
part because of the poor success rate of drug trials moving from mouse to human.  They 
found that responses are similar between humans and mice at, 6-12 hours.  However, the 
overall recovery time for genes to return to base line was drastically different between 
humans and mice.  Specifically, in the case of ARDS, mouse models show R2 
correlations between 0 and 0.8 with 47-61% of the genes shifting in the same direction.  
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Random chance is 50%, so the correlation between mouse studies approximates that of 
random occurrence.  The investigators also noted that despite all the potential causes for 
inconsistency in human responses (ie. age, different treatments, disease /trauma severity) 
the human case studies are highly consistent with each other.  In cases of ARDS human 
responses the R2 value of the correlation is .55, with 84% of the genes changing in the 
same direction.  Thus caution needs to be exercised in extrapolating results from mouse 
(and likely other rodent models as well) to human disease.  
  In the following sections we will examine the validity of the animal model’s 
response to SARS-CoV infection.  Animal models fall into three types: animal models 
using SARS-CoV isolates, animal models using rodent adapted SARS-CoV, and animal 
models using related coronaviruses.  
Animal Models of SARS Employing SARS-CoV 
Knowing the zoonotic origins of SARS-CoV it would seem that finding a good 
animal model for SARS would be straight forward.  However, this was not the case for 
SARS-CoV.  For some zoonotic diseases the natural host is unknown because these 
animals show no signs or symptoms of illness, while in others disease in the natural host 
is mild and transient, related to differences between the immune responses of the natural 
host and that of humans (164).  In the case of SARS-CoV the natural animal reservoirs 
show limited disease (bats and civit cats), whereas the human infection is more severe.  
Because of the limit disease in bats and civit cats other animals were examined for 
fitness to serve as a model for SARS-CoV infection and pathogenesis.  
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There are many factors that go into choosing an animal model.  The ability of the 
animal model to actually mimic the disease in humans is required, but one must also 
consider the cost of experimentation and the ease of working with the animals.  Different 
species of animals have differing responses to coronavirus infection, and so the models 
must be evaluated in terms of fitness compared to human SARS-CoV infection and 
disease.  In this section we will review the models that have been used in studying 
SARS-CoV disease.   
Primate models 
While primates are more closely related to humans than other animals, they are 
still unique in their responses to infection.  Primates are also very expensive to purchase 
and to house.  There is a demarcation between Old World Primates (ie macaques) and 
New World Primates (ie marmosets) and their responses to disease.  Both Old and New 
World primates are susceptible to infection by SARS-CoV (49, 138).  However, neither 
primate group are susceptible to a lethal SARS-CoV disease (99).   
Marmosets that were experimentally infected with SARS-CoV developed a 
multifocal mononuclear cell interstitial pneumonitis (49).  They also develop a more 
severe hepatic inflammation than human patients and the course of disease began at 2 
days and begin to resolve 7 days post-infection.  This is a shortened disease course 
compared to the course of human SARS which typically took 4 to 16 days to resolve.   
Macaque models have had mixed results as a viable animal model in the study of 
SARS-CoV infection.  One study reports the effects of SARS-CoV infection in rhesus 
and cynomolgus macaques (131).  Both rhesus and cynomolgus macaques had a limited 
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disease 2 or 3 days post infection, and all disease quickly resolved.  No animals 
demonstrated signs of respiratory distress, body temperatures remained normal during 
the study, blood chemistries and hemotologic parameters were, largely, unchanged.  A 
second study with cynomolgus macaques demonstrated that infection with SARS-CoV 
did not reproduce a severe illness, but did have results similar to the milder SARS-CoV 
infections seen in younger children (82).  A study that used an aged cynomolgus 
macaque model did show a disease that was similar to the severe SARS-CoV illness 
seen in elderly patients (138).  Using an aged macaque model researchers demonstrated 
that there is a difference between innate immune response in young animals and aged 
animals that are infected with SARS-CoV (138).  There were only 14 genes 
differentially regulated, of 518 examined, between the two age groups.  After infection 
of aged macaques there is a more robust induction of NF-κB regulated genes such as IL-
6, which has been implicated in SARS-CoV pathogenesis, than in young animals.  
STAT1 was differentially expressed between the two age groups, with its up-regulation 
being blocked in younger animals but not older animals.  Another study used 
cynomolgus macaques to evaluate pegylated interferon-α treatment of SARS-CoV 
infection (52).  The researchers do not state the age of animals used in the study, but 
report infection of type 1 pneumocytes by day 4 post infection, and extensive 
hyperplasia of type 2 pneumocytes by day 6.  The lungs showed multifocal, acute defuse 
alveolar damage with edema fluid mixed with neutrophils and extensive loss of alveolar 
and bronchiolar epithelium.  Animals that were pre-treated with pegylated interferon-α 
showed decreased viral titer in the lungs and the severity of the difuse alveolar damage 
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was reduced by 80%.  Animals that were treated with pegylated interferon-α after 
SARS-CoV infection also had reduced virus titer in the lungs.  The other study 
parameters showed a minor reduction in pathogenesis.  Macaques as a model for SARS-
CoV are limited in that the lethal disease is only seen in older animals, and it is difficult 
to obtain an appropriate number of older animals for study.  
Medium-sized mammals 
Other mammals that can be infected with SARS-CoV include civets, ferrets, and 
domestic cats (9, 92, 99).  These models are intriguing because these animals are less 
expensive and easier to handle than primates.  Cats or ferrets are also able to transmit 
virus to uninfected animals that are housed with them (9, 92) making them useful for 
epidemiological and transmission studies.  Cats do not show any lethargy or difficulty 
breathing, but they do show multifocal pulmonary consolidation in the lungs.  Cats also 
develop histological lesions in Peyer’s patches (9).  Although SARS-CoV replicates in 
the human GI track, lesions in the intestinal tract are not common in human cases of 
SARS.  Ferrets become lethargic from day 2 post-infection and also show multifocal 
pulmonary consolidation in the lungs but fail to develop lethal disease (165).  The ferret 
model has only used animals in a single age range and, to date, there have been no 
published reports of an aged ferret model.  There are histological lesions in infected 
ferret lung, liver, spleen, and tracheo-bronchial lymphnodes.  Civet cats, which were the 
intermediary host when SARS-CoV moved from bats, are capable of being infected with 
human and civet isolated SARS-coronavirus (80, 85, 99, 152).  They become lethargic, 
develop fever,  leucopenia and an interstitial  pneumonitis (165).  Civet cats do not die 
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from the infection, and recover about 13 days post infection.  There are some 
histological differences in the pulmonary histopathology from human SARS and the 
lesions found in civet cats lungs in that multi-nucleated syncytia are absent in civet cats.  
The lung pathology shows alveolar septa enlargement with macrophage and lymphocyte 
infiltration, with lesions similar to infected macaques. 
Golden Syrian hamsters 
  Syrian hamsters have also been proposed as a model for SARS-CoV infection 
(127).  Syrian hamsters, 5 week old females, support efficient viral replication that 
continues to 5 days post infection.  At day 2 post infection there is bronchial swelling 
and mild mononuclear inflammatory cell infiltrates in the bronchioles.  By day 3 post 
infection there are increasing mononuclear and polymorphomuclear cell infiltrates.  
Lung consolidation was the most extensive at day 7 post infection and affected up to 30-
40% of the cut surface of the lungs in some animals.  The disease resolved in 14 days 
with no mortality reported.  In hamsters low titers of virus were present in the liver and 
spleen at days 2 and 3 post infection, but not thereafter.  The animals developed a robust 
protective neutralizing antibody response by day 7, one that the researchers report was 
more robust than the antibody response in mice.     
Two other studies used the golden Syrian hamster model to evaluate monoclonal 
antibody therapy (126) and the immunogenicity of a live attenuated SARS-CoV 
infection (78).  When treated with monoclonal antibodies after infection 5 week old 
female hamsters showed a reduced viral burden (126).  Hamsters also showed reduced 
lung pathology by virtue of decreased interstitial pneumonitis and decrease lung 
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consolidation by day 7 post infection.  Neither response was dose dependent, though 
researchers did show that 4 mg/kg of antibody was not sufficient to protect from 
infection because not all hamsters had measurable levels of circulating antibodies in 
their serum.  The study evaluating the use of a live attenuated vaccine used 7 week old 
male hamsters vaccinated with a recombinant SARS-CoV Urbani strain or a 
recombinant SARS-CoV lacking the E gene (78).  After 4 weeks the hamsters were 
challenged with either SARS-CoV Urbani or a recombinant SARS-CoV with the spike 
protein of the GD03 strain of SARS-CoV.  All vaccinated hamsters had no detectable 
virus in the nasal turbinates by day 5 post infection or the lungs at any time post 
infection.   
While these studies are promising, the use of the Golden Syrian hamster is 
limited.  These animals do not suffer any type of obvious clinical disease and they 
completely resolve their lung lesions (127).  These animals also do not appear to develop 
the same clinical disease as in humans. The damage to the lungs does not appear to be 
immune mediated, so the use of healthy hamsters to study disease pathogenesis is 
limited.  To date there is no evaluation of aged hamsters, so it is possible that, like some 
mouse strains, there is a lung disease that develops in older animals.  There is an 
immunosuppressed Golden Syrian model that uses cyclophosphamide treatment of 
hamsters that leads to significant weight loss, expanded tissue tropism of SARS-CoV 
infection, and increases the viral pathology in the lung, heart, kidney, and nasal turbinate 
tissues (133).     This model is useful because the hamsters have a longer duration of 
illness, mortality being at 20-35 days post infection, depending on cyclophosphamide 
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treatment, and have a slower progression of SARS-CoV like disease.  However, because 
cyclophosphamide does cause lymphopenia, suppress B-cell activity and activation, and 
supresses regulatory T cell function this model is limited only to the study of viral 
replication and pathogenesis in the host and cannot be used to evaluate the effectiveness 
of vaccination or antiviral treatment in SARS-CoV infection.   
Rodents  
Rats and mice are commonly used laboratory animals in disease study.  Both are 
capable of being infected by a human SARS-CoV strain (17).  The virus will replicate in 
different inbred lab strains of mice.  However, non-transgenic or non-knock out strains 
of mice will not develop a human SARS-CoV pathology with a human SARS-CoV.  In 
order to generate a disease with a pathogenesis that is similar to SARS-CoV infection of 
humans the viruses must be passaged and adapted to mice or rats (22, 99).   
Mice make ideal animals to work with because of their low cost and the ability to 
genetically manipulate these animals.  As mentioned before, transgenic mice make for 
ideal tools to study infection and immune responses in coronavirus infection.   
Host-adapted viruses, viruses that have been passaged in an animal until there is 
a desired result, are useful in dissecting host-function specific genes.  These multiple 
passages in animals result in mutations that allow the virus to thrive in a specific 
environment (85, 178).  Adapted viruses are sequenced and then compared with the 
parent genome to find mutations that occurred and to attempt to correlate them to the 
adaptation.  Then animals can be infected with the parent or adapted virus and the 
animal’s immune response, ability to grow in target organs, and pathology can be 
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compared.  Adapted viruses have multiple components to their evaluation.   Because of 
the adaptation mutations the virus may not utilize the same set of pathogenic 
mechanisms as the parent virus does in humans.   These viruses are also useful in 
conjunction with transgenic animals.  Both mice and rats have adapted viruses that can 
be used to mimic a SARS-CoV like disease (22, 100, 101, 114, 123). 
Rats have been used in ARDS and ACE2 studies, and so seem like a viable 
option for an animal model of SARS-CoV infection and disease (12, 16, 27).  
Researchers developed a rat adapted SARS-CoV by serially passaging the SARS-CoV 
Frankfurt 1 strain, a mixture of the original virus without an ORF7a deletion and a 
variant virus that did have the ORF7a deletion,  ten times through young F334 rats (101).  
They found that adult rats (7 to 8 month old males) showed more severe acute lung 
injury with higher level of cytokines expressed than in the young (4 week old females) 
rats.  Young rats showed limited clinical symptoms and had pathology that was limited 
to the bronchi, bronchioles, and the alveoli with only mild edema around the blood 
vessels.  Adult rats became lethargic, had ruffled fur and abdominal breathing.  
Pathology showed congestion, edema, and consolidation of the lungs at days 3 and 5 
post infection.  They also had fibrin deposition and hyaline membrane formation in the 
alveolar ducts and alveoli.  There was no mortality in either young or old animals.   
 The limitation of this study is that there is no clear study endpoint.  The disease 
appears to resolve, though researchers do not state when clinical symptoms stop, and 
there is still virus reported in the lungs of young and old rats by day 21 despite the 
presence of neutralizing antibodies. Neither of these makes for a compelling argument 
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for rats as a model for human disease.  This study also fails to address the potential 
differences between older male and young female rats, since they did not maintain 
gender in the age groups.  This study also does not report if the adapted rat virus 
contains the ORF7a deletion as a majority or minority of the virus population.  They also 
do not address what other mutations, other than the spike Y442S, were required to adapt 
the Frankfurt1 strain to rats.   
 A mouse-adapted SARS-CoV that caused disease and mortality in previously 
resistant young BALB/c mice was first developed in 2007 (123).  SARS-CoV Urbani 
was passaged 15 times through BALB/c mice to generate MA15.  In 2009 Day et al 
reported the development of a new mouse adapted strain of SARS-CoV that could be 
used as a lethal model for SARS-CoV infection in BALB/c mice.  Strain V2163 was 
adapted to mice from SARS-Urbani after 25 serial passages.  This strain caused severe 
illness in 5-6 week old mice.  When MA15 and V2163 were compared it was found the 
V2163 was more lethal and produced higher virus titers in the lungs of infected animals.  
However MA15 was found to cause more weight loss and had a later mean date of death 
in older animals.  When compared genetically both strains contained a conserved 
mutation in the spike protein (Y436H), and both contained mutations in the membrane 
proteins, in nsp9, and in nsp13 that were not identical between the two strains.  Both of 
the strains elicit expression of IL-12, IL-6, MIP-1α, MCP-1, and RANTES.  They also 
stimulate low levels of IFN-γ, which is not seen in mice that are infected with SARS-
CoV Urbani.  MA15 stimulates significantly more MIP-1α and RANTES and V2163 
stimulates more MCP-1 compared to an infection with the Urbani strain.  V2163 
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stimulates 6-fold more IL-6 than MA15, which researchers believe demonstrate a 
correlation between IL-6 and mortality.   
Later studies used MA15 to study T cell responses that are required for 
protection for clinical disease (181, 182).  In one study, researchers found that the 
elimination of alveolar macrophages protected mice that were lethally challenged with 
MA15, but only in older mice, as depletion of alveolar macrophages in young mice had 
no effects on disease (182).  Mice that were depleted showed an earlier and more robust 
virus-specific T cell response, however it is possible that the use of clodronate to deplete 
the alveolar macrophages has an effect on T-cell responses independent of SARS-CoV 
infection, as animals that were treated with clodronate show higher pro-inflammatory 
cytokines pre-infection.  Weight loss was similar in infected and uninfected treated mice 
by day 2 post infection, but it is possible that the priming response may be affecting 
overall mortality.  Further studies with MA15 infected mice found that  SARS-CoV 
specific CD8 T cells were more protective than SARS-CoV specific CD4 T cells 
purified from lethally infected mice, and that the protection is dose dependent in animals 
in which activated CD4 and CD8 T cells were transferred individually or together (181).  
Both enhance survival in BALB/c mice that are lethally challenged with MA15.  They 
also found that immunization with dendritic cells that were coated with a specific spike 
peptide were almost 100% protective in BALB/c by induction of a specific T cell 
response in the lung and spleen.   
 Another study developed a strain of mouse adapted SARS-CoV, F-musX,  from 
the SARS-CoV Frankfurt strain (100).  Researchers found that disease was caused only 
 33 
 
in aged animals by day 2 post infection, with a mortality rate of 30-50%.  Lungs from 
aged mouse had significantly higher IL-4 and lower IL-10 and IL-13 levels before 
infection than young mice, whereas lungs from young mice lungs produced not only 
proinflammatory cytokines but also IL-2, interferon-γ, IL-10, and IL-13.  
The major drawback to the use of the MA15 or other mouse adapted SARS-
CoVs is the requirement of older mice for the development of lethal disease.  Aged 
animals are more difficult to acquire in large numbers and they are more expensive than 
younger mice.   
Other Betacoronaviruses as Models 
By comparing the members of the betacoronavirus group we can identify 
mechanisms of lung injury that occur during betacoronavirus infection.   Virus-unique 
contributions and mechanisms of pathogenesis, like contributions of the virus receptor to 
disease, can also be identified.  By virtue of being in the same betacoronavirus genus as 
SARS-CoV, MHV qualifies as a closely related virus that is capable of being used as a 
model.  However, the specific organ tropism of infection for many MHV strains makes 
them unsuitable as a model.  MHV-JHM and –A59 do not primarily infect the lung with 
MHV-JHM being neurotropic and MHV-A59 being both neurotropic and hepatotropic. 
The brain is considered an immune-privileged site, and so the cytokine/chemokine 
signaling and the cellular response will not be the same as in a less privileged organ, like 
the lung.   
Other betacoronaviruses have already been used to dissect the function of SARS-
CoV genes in vitro and in vivo both by the study of homologous genes and by placing 
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SARS-CoV proteins into an MHV virus that does not express a homologue to the SARS-
CoV gene  (57, 76, 113, 145).  One example is the study of nsp3, which contains 
multiple functional domains, one of which is called the X domain (76).  The X domain is 
not consistently conserved in coronaviruses.  The X domain is a functional 
monophosphatase, called ADP-ribose-1”-pase.  ADP-ribose-1”-pases are important and 
ubiquitous cellular processing enzyme involved in the tRNA splicing pathway, 
catalyzing the conversion of ADP-ribose-1 monophosphate (Appr-1-p) to ADP-ribose 
and are conserved in coronaviruses and in members of the “alpha-like supergroup” of 
phylogenetically related positive-strand RNA viruses that includes viruses of medical 
importance, such as rubella virus and hepatitis E virus (35). Researchers have 
demonstrated that the X domain is nonessential for replication in cell culture in human 
coronavirus 229E (76), but the ADP-ribose-1”-pase has been shown to be important in 
the liver pathology in MHV-A59 infection (35).  Another protein conserved amongst 
lineage one betacoronaviruses, but not SARS-CoV, is the ns2 protein.  The Weiss lab 
demonstrated that the MHV-A59 ns2 is a cyclic phosphodiesterase, similar to those 
functioning in tRNA metabolism, but its physiologic role is the hydrolyis of 2-5oligo(A), 
thus functioning to block the induction of RNaseL during MHV-A59 infection (130).  
Ns2 was found to be non-essential in cell culture (129), but was determined to be critical 
in liver infection (130, 184).  Ns2 activity is not important in all cell types.  It has been 
found to be important in bone marrow derived macrophages (183), but ns2 does not play 
a significant role in the infection of the brain (130).  Thus it is possible that ns2, which is 
present in other MHV strains, is important to the ability of the virus to replicate in 
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specific tissues.  In another study the SARS-CoV ORF6 protein was placed into a MHV-
JHM variant and it was discovered that ORF6 had a role in replication that was 
previously unable to be identified in SARS-CoV (57, 113, 145).  However, the MHV-
JHM strain does not produce pulmonary disease, but rather has the CNS as the primary 
target of infection.  Although these studies were helpful in understanding the role of 
SARS-CoV ORF6, they could not assess the role of ORF6 in the lung because JHM does 
not traffic to that organ.  When comparing the individual contribution of viral genes to 
pathogenesis it can become difficult to ascertain the role of individual genes.  While the 
nsp1 of SARS-CoV has been shown to play a role in cytokine dysregulation (81), it is 
important to note that the nsp1 of SARS-CoV is different, by sequence, and is shorter 
than the nsp1 of MHV.  It is possible that the differences in size are in nonfunctional 
regions or that the differences are purely host-related.  However, it is also possible that 
these sequence differences reflect important functional differences regarding the role of 
nsp1 in pathogenesis.   
In 2006 a study was published that examined that ability of multiple MHV strains 
to cause a SARS-CoV like disease in various inbred mouse strains after intranasal 
challenge (3).  This study showed that MHV-1 infection of 5-6 week old A/J mice 
induced a lethal pneumonitis that was similar to human SARS-CoV infection in terms of 
histopathologic changes and levels of type I interferon and cytokine responses.  A/J mice 
displayed multiple features observed in SARS-CoV infected patients including 
interstitial pulmonary infiltrates, hyaline membrane formation, multinucleated syncytia, 
congestion, hemorrhage in the lung, pulmonary edema and the presence of virus in the 
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liver.  Mice develop disease, demonstrated by weight loss, by 2 days post infection and 
usually die by 7-10 days post infection.  The disease is shorter in duration than human 
SARS, but it is lethal.   
A/J mice have a high incidence of spontaneous lung adenomas and tumors 
readily develop in A/J mouse lungs in response to exposure to carcinogens.  They also 
have a mutation in the IL-3 receptor α chain which is believed to play a role in the 
abnormal leukopoesis that is seen in these animals compared to C57BL/6 (59).  These 
mice are also susceptible to Legionella infection due to a polymorphism in Naip5, NLR 
family apoptosis inhibitory protein 5 (28).  A/J mice have an abnormal neutrophil 
physiology which is demonstrated as a decreased neutrophil infiltration in response to 
LPS compared to C57BL/6 mice (107).  A/J mice are also studied for their Th2 skewed 
T cell response to allergens as well as autoimmune diseases (2, 157, 163).  It is likely 
that one of these alterations to host immune system of the A/J mouse strain plays a major 
role in the immunopathogenic response to MHV-1 infection.     
In a series of experiments Khanolkar et al compared the T-cell CD4 and CD8 
responses in susceptible C3H/HeJ mice with the responses in non-susceptible B6 mice to 
MHV-1 infection  (71).  They found that in susceptible C3H/HeJ mice there was a 
stronger CD4 T-cell response that mapped primarily to epitopes contained in 2 regions in 
S protein, 2 regions in N protein, and 1 region in M protein.  In resistant B6 mice there 
was a stronger CD8 T-cell response that mapped mostly to S, and none of the CD4 or 
CD8 responses mapped to the N protein.  The CD8 T-cell response in B6 mice was ~11 
fold greater than the response in C3H/H3J mice, but the CD 4 response was ~4 fold 
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higher in C3H/HeJ.  From this they concluded that MHV-1 infection induces a more 
robust and broader CD4 T-cell response in susceptible mice, whereas resistant mice 
mount a more “broad and vigorous” CD8 T-cell response.  This may be due to the 
genetic background of the mice, as B6 mice lack the I-Eb allele and so they are I-Ab 
restricted; because of this restriction B6 are unable to bind certain peptide sequences.   
Similar to SARS-CoV infected patients there is a marked elevation of IL-6 and IP-10 
during MHV-1 infection (2, 27).  It has also been reported that in MHV-1 susceptible 
mice that the IFNγ-TNF-α coproduction by CD8 T-cells is reduced in the lung, but not in 
the spleen or lymph tissues.  Also CD4 coproduction of IFNγ-TNF-α is increased in all 
tissues compared to B6 resistant mice (70).  C3H/HeJ mice also had a higher fraction of 
IFNγ-IL-2 coproduction in the spleen and draining lymph, but not in the lung.  This was 
the opposite in B6 resistant mice which had more IL-2 production in the lung.  The 
reduced expression of TNF-α is similar to SARS-CoV infected patients, but IFN-γ 
usually remains unchanged in humans.    
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Figure 1. Schematic drawing of the genomes of murine hepatitis virus strain 1 (MHV-1) and severe acute respiratory 
syndrome coronavirus (SARS-CoV).  Both genomes are similar in ORF1a/b, but have different 3’ ends with different 
accessory proteins
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Table 2. Comparison of gene size (nucleotide length) between severe acute 
respiratory coronavirus (SARS-CoV) and murine hepatitis virus strain 1 (MHV-1) 
Virus Fragment Fragment Length, 
nucleotides 
SARS-CoV MHV-1 
Genome Size 29751 31386 
5’ UTR 246 191 
ORF1a 13133 13376 
ORF1a/b 21220 21499 
Spike 3767 4091 
Envelope 230 266 
Membrane 665 686 
Nucleocapsid 1268 1367 
Accessory Proteins  
(size nt) 
3a (824) 
3b (464) 
6   (352) 
7a (368) 
7b (134) 
8a (119) 
8b (254) 
9b (296) 
2   (797) 
HE (1268) 
4   (419) 
5a (323) 
I    (405) 
3’UTR 362 280 
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MHV-1 seems like an ideal model of pathogenesis.  MHV-1 requires no BSL3 
facilities, is a lower risk pathogen than SARS- or SARS-associated CoV, it naturally  
infects the lungs of mice, and creates a lethal SARS-CoV like disease in a specific 
mouse strain (A/J) while still causing non-lethal lung disease in other strains.  Because it 
produces a non-lethal pulmonary infection in most strains, various mouse strains can be 
used to evaluate gain of function or effect of genes in mutated or recombinant MHV-1 
viruses and to interrogate the role of specific host genes.  However, the MHV-1 model 
also has admitted limitations.  The absence of exact copies of SARS-CoV specific genes 
makes it difficult to evaluate those genes’ role in pathogenesis (Table 2, Figure 1).  To 
date no complete reverse genetic system is available for MHV-1, however there is a 
targeted recombination system that could be used to introduce some of the specific 
SARS-CoV genes into MHV-1and study their effect on pathogenesis in this model (83).  
Another considered issue is that because SARS-CoV utilizes ACE2 the virus is 
regulating a major signaling cascade that is not mimicked in other betacoronavirus 
models that use a different receptor.    
SUMMARY AND CONCLUSIONS 
Animal models will likely not be able to completely recapitulate disease and 
pathology that occurs during infection of humans with SARS-CoV.  Models should be 
able to accurately represent what occurs in human and should be able to do so in a 
manner that is safe for researchers and that is not overly expensive.  While primate 
models of disease are, generally, considered to accurately mimic human disease they are 
expensive and difficult to handle.  Smaller mammals are safer and less expensive to 
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work with and house, and but usually require host-adapted viruses to recapitulate human 
disease.  This still puts the researcher at risk by handling a virus closely related to the 
human infectious agent.  Related coronaviruses that are non-infectious to humans that 
naturally infect a small mammal are ideal in terms of cost and safety.  However, 
differences between humans and mice can make understanding the pathogenesis of 
SARS-CoV difficult. In fact, a recent publication has called into question the relevance 
of much of the mouse data regarding human inflammatory diseases (136).  However, in 
this review we have demonstrated that the models of SARS-CoV do, in part, mimic the 
disease course that is seen in humans not only in terms of cytokine/chemokine response, 
but also in histology and cellular pathology.  
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CHAPTER II 
MATERIALS AND METHODS 
 
VIRUSES AND CELL CULTURE  
Delayed brain tumor (DBT) cells were maintained at 37°C and 5% CO2 in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% calf serum 
(HyClone), 2% 0.2M glutamine (Sigma-Aldrich), and 1% penicillin-streptomycin (5,000 
IU/mL and 5 mg/mL respectively, MP Biomedical). Felis catus whole fetus (FCWF) 
cells were grown in DMEM supplemented with 10% fetal bovine serum (HyClone), 2% 
0.2M glutamine, and 1% penicillin-streptomycin at 37°C and 5% CO2. L2 cells were 
maintained at 37°C and 3% CO2 in DMEM supplemented with 10% calf serum 2% 0.2M 
glutamine, and 1% penicillin-streptomycin.  
The origin and growth of Murine Hepatitis virus strain 1 (MHV-1) (3) has been 
described.  MHV-1 was originally acquired from the ATCC® as isolate/strain VR-
261TM, plaque purified and then passaged it in DBT cells to expand.   
MHV-1 and recombinant MHV-1 viruses were propagated in DBT cells.  The 
recombinant feline MHV-1 (fMHV-1), in which the sequences encoding the spike 
protein ectodomain are replaced by the corresponding region of the feline infectious 
peritonitis virus (FIPV) spike protein ectodomain, was created for us in the Weiss lab.  
This virus was propagated in FCWF cells.   
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PLAQUE ASSAYS AND PLAQUE CLONING OF VIRUS  
Virus was prepared in 10-fold serial dilutions in DEM2.  Six-well cluster dishes 
were seeded with 0.8x106 L2 cells 2 days prior to the assay.  200μL of each dilution was 
placed into two wells of a cluster plate and incubated at room temperature for 1 hour on 
a rocking platform.  At the end of the incubation period wells were overlayed with 0.8% 
agarose containing DMEM supplemented with 2% calf serum, 2% 0.2M glutamine, and 
1% penicillin-streptomycin and incubated at 37°C and 3% CO2.  2.5mL of DME2/0.8% 
agarose mixture, warmed to 50°C was carefully pipetted into each well.  Clusters were 
maintained at 37°C, 5% CO2 for two days.  On the second day, if plaques were visible, 
the DME2/agarose layer was removed and the wells were stained with crystal violet.  
Excess stain was removed by gently flooding the wells with water until the water was 
clear.  Cluster plates were allowed to dry for at least 24 hours prior to counting or 
characterizing plaques.  
If plaques were to be picked the monolayer was not fixed and stained, rather on 
the second day of incubation plaques were identified by circling plaques with a marker.  
Plaques were picked using a pasture pipette into a small volume of DME2.  The agarose 
plug and any cells and debris in the plaque was pipetted up into the pasture pipette and 
was placed into a 1.5mL tube with 0.5-1ml DME2 and vortexed.  The plaque was stored 
at -80°C until passaged.  To propagate the virus contained in a plaque the DME2 
containing the plaque was inoculated into DBTs in a T25 flask that was at about 80% 
confluency.  The DBTs were incubated at 37°C in a 5% CO2 atmosphere and monitored 
daily for cytopathic effect.   
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GROWTH KINETICS ASSAY   
One day prior to the experiment six 96-well plates were seeded with 5x104 DBT 
cells per well (three wells per virus to be used in the study and additional control/surplus 
wells), fed with DME10, and incubated overnight at 37°C.  For each virus used in the 
study three wells of DBTcells (making three replicates per virus) were infected at an 
MOI of 3 by incubating them with viral inocula at room temperature for one hour while 
rocking.  After one hour one plate was stored at -80°C as the time zero time point, and 
the remaining plates were washed with DME0, cells were fed with DME2, and 
remaining plates were then incubated at 37°C until 4, 8, 12, 16, and 24 hours post 
infection where one plate was moved to -80°C for each time point. Once all the time 
points had been collected the virus was titered by plaque assay, as described above.  
RNA PREPARATION  
 For routine sequencing of virus 80% confluent DBTs were infected at an MOI 
≥1 and incubated for 8-10 hours.  When approximately 80% of the cells were either 
lysed or fused into syncytia, the cells were lysed with RLT+ βME, as described in the 
RNeasy Mini Kit (Qiagen) instructions.  Lysate was stored at -80°C until RNA was 
purified as described in the manufacturer’s protocol. 
TARGETED RECOMBINATION   
The original MHV-1 Donor plasmid was generated from MHV-1 infected cell 
RNA.  DBT cells were infected with MHV-1 at a multiplicity of 0.3 and total RNA 
extracted at 7 hours post infection using an RNEasy Mini Kit.  The freshly prepared 
RNA was used as template for cDNA synthesis (Superscript II, Invitrogen) with primers 
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specific to regions containing the structural genes. For the region encompassing the HE 
gene from codon 28 extending into the E gene, cDNA was primed with an 
oligonucleotide designated E60-40rev with the sequence 
GACTATAAAAATAATCTGCC. The resulting cDNA was PCR amplified with the 
forward primer HE28-BsmBI-FW-new (sequence 
GTACGTCTCAACCTCTCAACATCGTTTCAC), containing a BsmBI site at its 5’end 
to facilitate later recombinant addition of the MHV 467 nucleotides from the 5’ end of 
the genome with a T7 promoter, and the reverse primer E60-40Rev using a mixture of 
Vent and rTth DNA polymerases as described previously (28). The resulting amplicon 
designated HE-S was TA cloned into pGEM-T Easy (Promega).  Similarly, a cDNA that 
would encompass the 3’ end of the genome was synthesized by RT-PCR using primer 
N-RV-SfiI (GGCCATTTAGGCCTTAATTAA(T)15GTGATTCTTCAATTGGCC) for 
the cDNA synthesis reaction and amplified with S45-FW5 
(GCGATTGGTGCTATACAGG, nts 4109-4128 in GenBank Accesssion EF682498) 
and N-RV-SfiI primers for the PCR step. The amplified DNA fragment extending from 
nucleotide 4109 to the 3’ poly (A) tail in Genbank Accession EF682498 was 
subsequently TA cloned into pGEM-T Easy and two clones designated SN#4 and SN#13 
were obtained.   A cDNA extending from position 1379 - 5477 and containing the S 
gene from codon 9 was similarly RT-PCR amplified with a forward primer, 
CCTAATACCCTCTTGCCTAGGGTATATTGGTGACTT, and a reverse primer, 
CTGTCCTTCCACCTGCAGGTGTACATCTAGTCAATCCTCG. To allow subsequent 
recombinant DNA manipulations, the forward primer contained two coding silent 
 46 
 
mutations in codons 13 and 14 of the spike gene (T1394C and T1395C relative to 
GenBank Accesssion EF682498) to introduce an AvrII site (underlined in the primer 
sequence).  The reverse primer introduced mutations G5458C, C5460T, T5461G, 
T5463A, C5464G, and C5465G (all mutations are in the positive sense) to introduce the 
SbfI site (underlined in the primer sequence) 3’ to the spike gene termination codon and 
prior to the gene 4 transcriptional regulatory sequence.  The resultant cDNA fragment 
was TA cloned into PCR 2.1 Topo and designated clone 4B.  All clones were sequenced 
in their entirety.  The first 467 nucleotides of MHV-1 containing the entire 5’UTR and a 
portion of ORF1a was amplified with a forward primer containing a T7 promoter 
followed by MHV-1 sequences 1-21 and a reverse primer that contained a BsmBI site.  
The 5’ UTR with a T7 promoter was fused to the remainder of pDonor utilizing the 
BsmBI site at the 5’ end of the HE sequence contained in this plasmid.   
A recombinant MHV-1, designated fMHV-1 was generated for us in the Weiss 
lab using targeted recombination.  Briefly, a restriction fragment containing the Feline 
Infectious Peritonitis Virus (FIPV) spike protein ectodomain fused to the highly 
conserved MHV-A59 transmembrane and cytoplasmic domains was excised from 
pfMHV (75) by digestion with AvrII and SbfI and exchanged with the corresponding 
MHV-1 sequences in pDonor to produce the plasmid pDonor-SFe. fMHV-1 was 
generated by targeted recombination by electroporating in vitro synthesized T7 
transcripts from pDonor-SFe into L2 cells that had been infected with MHV-1 and 
overlaid on FCWF cells to select viruses that had acquired the ability to enter and 
replicate in feline cells.  One recombinant virus, designated fMHV-1, was then plaque 
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cloned and expanded in FCWF cells.  This virus was then used in later targeted 
recombination experiments as the acceptor virus.     
Recombinant MHV-1 viruses were generated by targeted recombination 
essentially as described in Kuo et al. (75) with the exception that fMHV-1 was used as 
the acceptor virus and transcripts from pDonor and mutant versions of pDonor were used 
as donor RNAs, rather than transcripts from the MHV-A59 based plasmid, pMH54.  
pDonor plasmids were digested with PacI to linearize the plasmid.  pDonor RNA was 
transcribed using mMessage mMachine® T7 Transcription kit (Ambion) as previously 
described (75).  FCWF cells, at approximately 80% confluence, were washed in DMEM 
and infected with fMHV-1 at an MOI of 0.5 to 1.0 for one hour.  After infection with 
fMHV-1 cells were fed with supplemented growth media and incubated at 37°C, 5% 
CO2 for 6-8 hours prior to transfection.  RNA was transcribed the day of infection and 
was transfected into infected FCWF with the Nucleofector using Kit V, protocol T-21 
according to manufacturer’s instructions (Lonza Corp.).  Infected/transfected cells were 
then overlayed onto subconfluent, ~40%, DBT cells and incubated as described for 3 
days (75, 83).  Cells were visually monitored and on day 3 were blind passaged onto 
fresh DBT cells to further enrich for recombinant viruses that had regained the ability to 
infect murine cells.  If syncytia and plaques were visible in the blind passage then virus 
was plaque purified on L2 cells.  If no signs of infection were present in the first blind 
passage, a second passage was done prior to plaque cloning.  Recombinant plaque 
purified virus that was recovered was expanded in DBT cells and viral RNA was 
collected from infected cells.  RNA was purified using the Qiagen Kit according to 
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manufacturer’s instruction and reverse transcribed as described and the cDNA was 
sequenced to confirm the presence of the desired genetic markers (for primer list see 
Table 4).   
CONSTRUCTION OF CDNA CLONES 
DBT cells at a confluence of 80% were infected with MHV-1 at a MOI of 0.5-1.0 
and the infection was allowed to proceed until 80% of the cells were dead or or in 
syncytia.   Cell supernant was removed and centrifuged at 2,000 rpm to clarify and 
remove cellular debris.  Virus in clarified supernant was partially purified by pelleting 
through a 30% (w/w) sucrose pad at 4°C, 25,000rpm, for 3 hours using the Sorvall 
SW28 rotor (Sorvall Ultracentrifuge, Thermo Electron Corp).  Pelleted virus was 
resuspended in Tris-buffered saline containing 20U of RNase (RNase cocktail, 
Invitrogen) and 40U of DNAse (Turbo DNase, Invitrogen) and digested at 37°C for 60 
minutes.  Viral RNA was extracted with either the RNA-Easy kit (Qiagen) or the RNA 
Mini kit (Bioline).  RNA was converted to cDNA using Super Script III (Invitrogen) and 
a MHV-1 specific primer (Table 3).   cDNA fragments ranging 2 to 5 kb were then 
amplified using long, accurate PCR using a mixture of Vent (New England Biolabs) and 
rTth (Invitrogen) DNA polymerases as described previously (83) with the MHV-1 
specific primers listed in Table 3.  Fragments were also amplified using the Kapa HiFi 
Master Mix (Kapa Biosystems,) according to the manufacturer’s instructions. Fragment  
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Table 3.  Primers used to generate the MHV-1 Complete Reverse Genetic System 
fragments.  
MHV-1 
genome 
position Purpose 
Primers 
 (lower case red letters indicate planned mutations, bold 
underlined indicate addition of restriction sites) 
1-21bp A start Fw’ GTACCCTCTCAACTCTAAAA 
4838-4868  
A/B junction 
Rv’ GCTCTTCTTTgTAACAAGACGCCAGTCTGTGGGCAG
 908-914  
Δ BsQI 
internal mut GGCGTATGCaCTcCTTAAGGGCTATCGC 
4863-4887 
A/B junction 
Fw’ GCTCTTCAcAAATTTGATAGTGTTGATGGTG 
9500-9518 B end Rv’ CCACTGAACTTGCCGTTAA 
8877-8897 C start Fw’ GGTATGAGTCTACATTTGGTC 
11438-
11461 
C/D junction 
Rv’ GCTCTTCTGgTTTATGCTGCGCATGGTGAC 
11455-
11479 
C/D junction 
Fw’ GCTCTTCAAAcCACGACGTCTTCTCTATTATG 
13006- 
12986 
D/E junction 
Rv’ GCTCTTCTAAGTATAGCATACACAATCCTGCCC 
13006-
13031 
D/E junction 
Fw’ GCTCTTCTACTTAGTGACTGTGACGGTCTCAAG 
15704-
15683 
E/F junction 
Rv’ GCTCTTCATgACATTAGGTATAGGCGC 
15699-
15721 
E/F junction 
Fw’ GCTCTTCTGTcTACCGCGCGGACCATGTTG 
19108-
19090 F mid Rv TAGGGTTGCCAATGTCATA 
18920-
18940 F SbfI Fw ATGCTATCATGACTCGATGCT 
21513-
21497 F SphI Rv AGCCCCTCCATTCCACA 
18942-
18961 Fmid Fw AGCTGTCCATGATTGCTTTT 
22666-
22688 
F/G junction 
Rv’ CGGACCGACTGTCACCAAATAGA 
22689-
22700 
F/G junction 
Fw’ CGGTCCGACTGTAACTATG 
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sizes are as follows: A, 4868 nt; B, 4655nt; C, 2584nt; D, 1531nt; and E, 2677nt.   The F 
fragment (6999nt) was PCR amplified in three parts where native SbfI and SphI sites 
between 22662 and the start of G were used to ligate the fragments together.  cDNA was 
cloned into the LC-Kan vector (Lucigen) per manufacturer’s protocol.  Clones were 
picked and sequenced to confirm the presence of the desired insert as well at to confirm 
if the sequence matched the NCBI MHV-1 genome (Accession FJ647223.1).  The G 
fragment was generated by using a forward primer that contained an RsrII site and PCR 
amplifying the region between the HE gene and the AvrII site introduced into S with 
pDonor as the template.  The PCR fragment was cloned into a pGEM T-Easy (Promega) 
vector and the RsrII fragment was introduced into the G fragment by restriction fragment 
exchange.  Deviations from the MHV-1 genome that we wished to correct were 
corrected by restriction digestion and fragment swapping or site-directed mutagenesis.  
Site directed mutagenesis was done using the QuikChange II XL Site Directed 
Mutagenesis kit (Stratagene) per manufacturer’s instructions.			
COMPLETE REVERSE GENETIC SYSTEM		
         Primer boundaries and fragment sizes were selected based on previously designed 
MHV  Complete Reverse Genetic Systems (Figure 2) (176, 177).  We elected to use 
BspQI, a Type IIS restriction enzyme rather than BsmBI employed in for the MHV-A59 
(176) and MHV-JHM (personal communication, Weiss lab) reverse genetic systems, 
because the number of native BspQI sites that would need to be eliminated during 
construction were fewer in the MHV-1 genome than if we had used BsmBI. There is a 
native BspQI site located in the “A” fragment.  Because of this a mutagenesis primer 
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was designed to make non-coding mutations to remove the native BspQI (Table 3).  A 
second BspQI site is located in a highly conserved region of coronavirus genomes, 
called the “octomer”(46).  We elected to introduce a RsrII site, to avoid altering this 
highly conserved region, to join the “F” and “G” fragments, a strategy that has been 
previously employed for constructing a targeted recombination plasmid and shown to 
have no effect on replication of the resultant virus (75). Primers used to introduce point 
mutations or restriction digestion sites into the fragments are listed in Table 3.   
PLASMID CONSTRUCTION  
Amplified cDNAs were cloned into the pSMART LC-KAN vector (Lucigen 
Corp.) according to the manufacturer’s instructions.  Plasmids were sequenced to 
confirm sequence identity to the reference MHV-1 sequence posted in GenBank, 
accession FJ647223.1, which is missing the first 25 nucleotides.  To generate the entire 
MHV-1 genome sequence we combined FJ647223.1 with Murine hepatitis virus strain 1 
leader plus the most 5’ part of ORF1ab, GenBank accession EF682499.1.  Mutations 
found in the clones were corrected either by restriction fragment exchange with clones 
not containing a particular mutation or by site directed mutagenesis.  Site directed 
mutagenesis was performed with the QuikChange XL kit (Agilent Technologies) 
according to manufacturer’s instructions.   
CDNA FOR WHOLE GENOME SEQUENCING 
 Approximately 20 T175 flasks of 75% confluent DBT cells were infected with 
MHV-1 P2 or P3 stocks at a MOI=.01-.05 and cultures incubated for 24-48 hours until 
CPE completely involved the monolayers and cells were beginning to detach. The 
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infected cell supernatants were collected and clarified by centrifugation at 20,000 rpm 
(rotor 42) for 30 minutes at 4°C in a refrigerated Sorvall RC6 plus centrifuge.  Virus was 
pelleted through a 30% sucrose (w/w) in MSE buffer (10mM MOPS, pH 6.8; 150mM 
NaCl; 1mM EDTA)  pad at 25,000rpm for 2.5 hours in an SW28 rotor in a Sorvall 
Ultracentrifuge.  The supernates were decanted and the pellets were resuspended in MSE 
buffer (total volume <1 ml) and then placed on a continuous 20-60% sucrose gradient 
and centrifuged overnight at 25,000rpm.  The opalescent virus-containing band was 
collected by puncture and aspiration with a needle and syringe, diluted to a total volume 
of 11.5 ml with MSE, and virus was pelleted by centrifugation in an SW41 rotor at 
35000rpm for one hour.  The virus-containing pellet was resuspended in 200μL MSE 
buffer per pellet, multiple pellet volumes were combined and incubated with 20U RNase 
and 20U DNase for 1 hour at room temperature in order to remove any pelleted nucleic 
acids from co-sedimenting material.  Viral RNA was extracted with the Qaigen RNeasy 
Mini kit per the manufacturer’s instruction.  Viral RNA was converted to cDNA using 
both MHV-1 specific primers, random primers, and a polyT-containing primer specific 
for the MHV 3’ end.  For first strand synthesis, purified viral RNA and 2µg of random 
hexamer primer (Takara, catalogue no. 3801), 1µg of (dT)15 GTGA (a primer specific 
for the 3’UTR of MHV), and 83ng of MHV-1 specific primers listed in Table 4 were 
reverse transcribed with Superscript III (Invitrogen).  Primers were annealed by 
incubating at 65°C for 5 minutes and placing on ice for 2 minutes.  cDNA synthesis was 
initiated by the addition of 4μL of 5x First-Strand Buffer, 2μL of 0.1M DTT, 1μL of 
10mM dNTPs, and 0.5μL of RNase inhibitor (Ambion or New England Biolabs), 
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incubating at 25°C for 2 minutes and adding 1μL of Superscript III Reverse 
Transcriptase.  The reaction was continued at 25°C for 10 minutes, 42°C for 60 minutes, 
and 70°C for 15 minutes.  For second-strand synthesis 20μL of the first-strand reaction 
was mixed with 59.5μL of water, 10μL of NEBuffer2, 1.5μL of 1M (NH4)2SO4, and 3μL 
of 10mM dNTPs and incubated on ice for 5 minutes.  RNase H (NEB M0297) was 
added at 1μL and DNA polymerase I (E. coli, NEB M0209) was added at 5μL and the 
reaction was incubated at 16°C for 3 hours.  The double-stranded cDNA was purified 
with the PCR purification kit from Bioline (BIO-52057) and the concentration was 
determined with a NanoDrop spectrophometer.  The cDNA was taken to the Borlaug 
Institute (Texas A&M University) where it was purified, and a library for Illumina 
sequencing was constructed by the staff.   
COMPLETE GENOME SEQUENCING AND ANALYSIS  
Sequence was obtained with the Illumina HiSeq 2500 and was analyzed using 
CLC Genomics Workbench 6 software (CLC Bio).  A Qualitative Variant analysis was 
run at 10%, 5%, and 2% on sequence aligned to a whole MHV-1 genome that is a 
combination of the MHV-1 genome (FJ647223.1) and the MHV-1 5’ UTR leader 
(EF682499.1), which added 25 nucleotides to the 5’ end of the MHV-1 genome 
submission in GenBank.  We set the Neighborhood radius at 5, the Maximum gap and 
Mismatch count at 2, the Minimum Neighborhood quality at 10, we ignored non-specific 
matches, and the minimum coverage was set at 10.  Because of our primer selection we 
did not require the presence of the mismatch in both forward and reverse reads.   
 
 54 
 
SUBCLONING AND SEQUENCING OF NSP13 AND NS4  
MHV-1 P2.2 was inoculated onto subconfluent DBT cells (~80%, T175) at an 
MOI of 0.1 by removal of the media from the cells, washing with DME0, addition of the 
supernant, rocking at room temperature for one hour, removal of the media, and feeding 
the cells with DME10.  Cells were incubated at 37°C, 5% CO2 for 20 hours.  After 20 
hours the supernant was removed and clarified and 1mL was passed onto a new T175 
flask of subconfluent DBT’s (~80%) and was inoculated as described above.   
The cells from the T175 were lysed with lysis buffer RLT with 10% β-
mercaptoethanol (Quaigen, RNAeasy).  Manufacture’s instructions were followed to 
extract RNA.  SuperScript II (Invitrogen) was used to reverse transcribe cDNA for the 
nsp13 region (primers: F822 (GTGAGGACCATAAGCCACAG), MHV-1_17145-22RV 
(CTGTACAGTACAATAGCGCTTCAT)) and ns4 (S45 FW7 
(AATTGTTGTGATGAGTATGG), EfixC-TRV(GGGGACAGCAACAAAGTA)) in 
separate reactions.  This was done for P3.2 and P4.2. 
A ten percent lung homogenate was prepared from a mouse infected with MHV-
1 (P2.2) and euthanized on post infection day 3 and clarified by low speed 
centrifugation.  The clarified homogenate was then pelleted through a 30% (w/w) 
sucrose in MSE pad for one hour at 40,000rpm using a TLS55 rotor in the Optima TLX 
Ultracentrifudge (Beckman Coulter).  The pellet was resuspended in 200μL of lysis 
buffer RLT with 10% β-mercaptoethanol and RNA was extracted per manufacturer’s 
instructions.  Superscript II was used to reverse transcribe cDNA as described above.   
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cDNA was PCR amplified using the 5’Master Mix (5’Prime, 2200100) and the 
resulting product was cloned into the pGEM T Easy vector, per manufacturer’s 
instructions (Promega).  Colonies from P3.2, P4.2, and lung nsp13 and ns4 ligations 
were picked and sequenced to verify the presence of the variant nucleotide found during 
whole genome sequencing.    
CARE AND INFECTION OF ANIMALS  
 Female A/J mice between 5 to 8 weeks of age (Charles River Laboratories or 
Jackson Laboratories) were maintained in microisolator cages and fed standard lab chow 
diet and water ad libitum. Mice were held for varying lengths of time, no less than 2 
days and no more than one week, and allowed to acclimate before being infected.  Mice 
were anesthetized by exposure to isoflurane for infection with MHV-1.  Once 
anesthetized 50µL of virus diluted in ice-cold DMEM supplemented with 2% serum, 2% 
glutamine, and 1% Penicillin-Streptomycin was instilled onto the nares, and mice were 
observed until the virus was inhaled. Mice were weighed daily, and percent oxygen 
saturation determined with a MouseOx® pulse oximeter, and monitored for symptoms of 
disease including ruffled fur and visible difficulty breathing. Mice were euthanized if 
they lost more than 20% of their start weight or if they had oxygen saturation levels 
equal to or less than 80%. At various times postinfection, mice were sacrificed by lethal 
CO2 exposure. Lungs, livers, and brains were collected and analyzed for viral titers and 
histology as previously described (83). Processing of organs for histology is described 
below. Samples for viral titration were weighed and 10% homogenates (w/w) were 
prepared with supplemented DME2.  The organs were homogenized manually in 
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Dounce homogenizers and then the homogenized sample was clarified by low speed 
centrifugation and virus titers determined by plaque assay.   All protocols were approved 
by Animal Welfare Committees and complied with NIH guidelines.  
MEASURING OXYGEN SATURATION 
 Oxygen saturation levels were measured and recorded in mice using the 
MouseOx® pulse oximeter (Starr Life Sciences Corp.)(154).  All measurements were 
taken while the mice were awake, using the small size collar clip from Starr Life 
Sciences.  Oxygen saturation, pulse, and breathing rate was measured and recorded for at 
least 30 seconds.  Data was reviewed to make sure there were no error messages.  Any 
measurements with error messages relating to oxygen saturation or lost signal (error 
code 4, 6, or 7) were deleted from the data set.    
HISTOLOGY  
 Organs that were collected from mice were placed into a 4% paraformaldehyde 
solution for at least 24 hours, organs were sectioned and sent to the Texas A&M 
Veterinary Integrative Biosciences Histology laboratory where samples were embedded 
in paraffin, sectioned, and stained with hematoxylin and eosin per the histology 
laboratory’s protocol.  Sections of the lung from all groups and controls were examined 
by light microscopy. Assessment of the degree of lung pathology was scored from 1 to 4 
as follows: Extent, alveolar thickening and inflammation, edema, desquamated cells, and 
presence of hyaline membranes. 
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Table 4. List of MHV-1 primers for sequencing confirmation 
Genome Start Primer 
23779 GTGTCTTATTGGGTATAGC 
24487 CATTTTTACCAACAGGG 
28135 CAATAAATAACTAGGCC 
25301 ATGGCGATACTSTGGCTGG 
25551 AATGTGGTGGAAGCAACG 
25601 AGAAAATGTGGCAGCG 
26467 GGAACTTAGCGTGACACC 
26722 CATAAAAGTGCTGCCTCC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 58 
 
 
Table 5. List of Primers used for the MHV-1 whole genome sequencing 
Primer name Primer Sequence 5’ to 3’ 
5’FW GAGTGATTGGCGTCCGT 
5’ RV CTTACGAAGAAGGATGG 
A406 TCAGTCCGCCATAATCCG 
A1356 ATTGCTGTGGTGACGC 
A2973 GAGGCGATGAAGTGATTG 
A3400 ACTTAATGCGCCAGCGGAC 
B514 ATGGCAGGAGGCTTGGAA 
B1773RV AAACCACATATCTACACCC 
B1510 TGCCAATGAGTTCTGAT 
B2826 ATGGCTAACGGCGGC 
B3907 ATGGTGTGCTAAGGGAT 
B4291 ATGCCTCTCTGTA 
D1215 TTCAAGATGCTGATGGCG 
E469 TTGGCGAGATGGTAGC 
E1293 TACTTATAGGGAGTTCGACC 
C723 GCTGTGGTTGGATGATA 
C1068 CTGCGGTTCTGTAGGAT 
F365 AGCGTTCTCTTGATAGAGCG 
F1826 CCTCGTGTGCTACTGAATAAGG 
F2771 GGAATGTTTGCCGAGAGAG 
F3023 TGTAGTGTCTGCAACAAGCG 
F4607 AATGAAGCTCTAGCACGTGG 
F5563 TCGTGACAAGTTGGCTCTG 
F6386 GATCCCACACTGCACAGTG 
MHV3’UTR CCTGGGAAGAGCTCACAT 
C1451 GATTCCAGGGTAAACAAA 
HE308FW CAATTATACGGGTGAGGGAGAC 
HE35208 AATGAGAGCTACATCAACCTC 
S45 2957FW CATAAAAGTGCTGCCTCC 
S45 FW8 AAACCTCATCTTAATTCTGG 
S45 FW3 AATGTGGTGGAAGCAACG 
E1to22 ATGTTTAATTTATTCCTTACG 
N 643-663 CCAAATAATCGCGCTAGAAG 
 59 
 
 
 
Figure 2. Schematic of MHV-1 genome and schematic to assemble a complete infectious cDNA clone.  The component 
clones junctions are shown relative to their position in the MHV-1 genome.  The A fragment has a T7 promoter cloned 
in front of the 5’ untranslated region (UTR).  Clones A-F encompass Open reading frame (ORF) 1a and 1a/b which are 
proteolytically cleaved to form nonstructural proteins 1-16 (ns1-16).  Clone F also includes nonstructural gene 2 (ns2) 
and a portion of the hemagglutinin esterase (HE) gene.  The G clone includes the 3’ portion of the HE gene and the 
remaining structural genes and strain specific non-structural genes: spike, nonstructural gene 4 (ns4) and 5a (ns5a), 
envelope (E), membrane (M), nucleocapsid (N).  G also includes the 3’ UTR.  Native BspQI sites are not shown in this 
figure (see Chapter 5).
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CHAPTER III 
GENETIC MANIPULATION BY TARGETED RECOMBINATION PRODUCES 
RECOMBINANT VIRUSES THAT HAVE AN IN VITRO PHENOTYPE IDENTICAL 
TO NON-RECOMBINANT VIRUS BUT ARE NOT PNEUMOPATHOGENIC AND 
MHV-1 RAPIDLY ATTENUATES IN CELL CULTURE 
 
INTRODUCTION 
In November of 2002 a Severe Acute Respiratory Syndrome (SARS) disease 
began in China and spread to Hong Kong, Singapore, Vietnam, Taiwan, and Canada (14, 
106, 150).  It was discovered to be a new coronavirus that was named SARS-CoV (31, 
109). SARS-CoV infection has not been seen outside laboratory source infections since 
2003 (14). The new SARS-CoV was found to be a relation to the group 2 coronaviruses, 
with viruses like Mouse hepatitis virus (MHV) (72). Coronaviruses are known to cause a 
variety of diseases in animals, and was only thought to cause limited upper respiratory 
infections in humans (98, 110, 187).  However, SARS-CoV causes severe pulmonary 
disease characterized pathologically by acute alveolar damage and virus has been found 
systemically in infected patients (105, 116, 147, 166).  
Coronaviruses have a 5’ untranslated region (UTR) that has important RNA 
structural features that contribute to replication (67, 168).  Following the UTR are two 
large open reading frame (ORF) that generates a large polyprotein via a -1 frameshift 
(10, 25).  In general coronaviruses have, after the ORF1ab region, a series of virus-
species specific genes (so-called accessory genes) dispersed amongst genes that code for 
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structural proteins.  Two other pathogenic human betacoronaviruses, CoV-HKU1 and 
HCoV-OC43 contain a hemagglutinin esterase gene (HE), as do many strains of MHV 
but SARS-CoV and other SARS-like-CoV do not.  MHV-1 also does not contain a 
functioning HE gene (170).  All coronaviruses encode the spike protein (S), envelope 
protein (E), membrane protein (M), and nucleocapsid protein (N), in that order, in the 3’ 
third of the genome and this is followed by an untranslated region that is functionally 
important (72, 160).  Encoded with the S-E-M-N are strain specific accessory genes that 
greatly vary between coronaviruses (40, 53, 160).        
The more recent 2012 emergence of the Middle East respiratory syndrome 
coronavirus show a continuing need for animal models of severe coronavirus disease (5, 
26, 62, 97). There have been several animal models proposed for SARS-CoV disease 
including mouse-adapted SARS-CoV, ferrets, cats, Syrian hamsters, and non-human 
primates (9, 22, 23, 125, 127).  All of these models use SARS-CoV or a host- adapted 
SARS-CoV to study disease in the animal.  In 2006 De Albuquerque demonstrated that 
MHV-1 infection of 6 week old A/J mice produced a disease that was clinically similar 
to SARS-CoV in humans (3).  In infected A/J mice the mononuclear cellular infiltrates, 
fibrin deposition, hyaline membrane formation, and the cytokine response was similar to 
activity and responses seen in SARS-CoV patients.  This MHV-1 model is more 
convenient and less expensive than any of the models using SARS-CoV or its 
derivatives because MHV-1 can be used in a BL2 setting and reduces the potential 
hazards to human scientists.  
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In order to study the genetic contributions of viral genes to pneumopathogenicity 
a method to introduce mutations into viral genes is required.  Targeted recombination 
has been used in other MHV strains, such as –A59 and -JHM, to manipulate the 3’ most 
genes to study their functions and effects on viral replication and pathogenesis.  Targeted 
recombination takes advantage of the naturally occurring RNA recombination events 
that can occur during coronavirus replication (69, 89).   Originally the system was 
developed using temperature sensitive mutants but in 2000 Kuo et al developed  the 
spike protein as a selector for positive recombination events (75).  By generating a 
mutant MHV virus that expressed a spike with a unique tissue tropism, recombination 
events upstream of S could be screened for by using mixed cell cultures and then passing 
progeny virus onto cell cultures that would select for the desired recombination events.  
This method has been successfully used in generating recombinant MHV-A59 and 
MHV-JHM viruses, as well as A59 or JHM recombinants that express the MHV-1 spike 
in isolation or the MHV-1 genes from the spike to the 3’ UTR (8, 58, 83, 102, 103).   
Our lab had begun developing the targeted recombination system for MHV-1 
(83) and to date have been working on generating an isogenic control virus to use for the 
MHV-1 targeted recombination system.   In 2010 Leibowitz et al demonstrated that 
expression of the MHV-1 S gene within the MHV-A59 background (rA59/SMHV-1) 
increased the pneumovirulence of MHV-A59 (83).  Mice that were infected with 
rA59/SMHV-1 recombinant virus developed pulmonary lesions that were similar to those 
observed with MHV-1, although it was significantly less virulent than either MHV-1 or 
MHV-A59. 
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RESULTS 
Recombinant MHV-1/S 
Our lab generated the donor plasmid (pDonor) for a MHV-1 targeted 
recombination system (83) (Figure 3).  The plasmid was used to generate an isogenic 
control plasmid where the MHV-1 spike (pDonor-1) was swapped back in to generate 
isogenic control virus (MHV-1/SMHV-1).   Our plasmid contained known mutations that 
were required to generate a donor plasmid that could be used with other established 
MHV targeted recombination systems, as well as additional mutations that were 
acquired during the cloning process.  An AvrII site was introduced at the 5’ end of the 
spike region, two BsmBI sites were eliminated in the spike, and a SbfI site was 
introduced in the short non-coding sequence 3’ of the spike protein coding sequence.  
All sites were non-coding mutations and were made to ensure that codon usage would 
not be negatively affected.  During the generation of the portions of the pDonor plasmid 
a coding mutation was introduced into the 5a gene and a non-coding mutation was 
introduced into the E gene.  Also a G was deleted from the 3’ side of the SbfI site.  
These mutations were left in the plasmid because the only coding mutation was in the 5a 
gene, which, at the time, had no function assigned and had never been demonstrated to 
produce detectable levels of a protein product.   
Two independent isogenic recombinant viruses were generated and plaque 
purified and four recombinant viruses were compared to MHV-1 (P3) in plaque size 
analysis (Figure 4).  None of the recombinants were significantly different from non-
recombinant MHV-1 in plaque size.   
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Figure 3. pDonor plasmid map.  The pDonor plasmid consists of a T7 promoter 
joined to the first 467 bases of the MHV-1 5’UTR and adjacent ORF1ab sequences 
and were joined to a plasmid that housed the HE-3’UTR of MHV-1.  The plasmid 
was engineered to have an AvrII, SbfI, and a PacI site.  Two BsmBI sites and an 
AvrII site were eliminated by point mutations (*).  In the process of generating the 
SbfI site a G nucleotide was deleted (#).  In the process of generating the plasmid a 
coding mutation was introduced into gene 5a (@) and a non-coding mutation was 
introduced in the E (*).  
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Figure 4. Plaque size comparison of MHV-1 and MHV-1/SMHV-1 recombinants 
generated by targeted recombination.  Two independent targeted recombination 
reactions were used to generate a MHV-1/SMHV-1 virus.  Isolates were plaque 
purified and plaques were selected and expanded.  Plaque size was compared to 
MHV-1 to verify a homogeneous pheynotype in cell culture. 
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While we established that the MHV-1/SMHV-1 virus was not significantly different 
from MHV-1 in its plaque phenotype in cell culture we also generated spike recombinant 
viruses. The pDonor plasmid described above was used for targeted recombination to 
generate recombinant MHV-1 strains containing the MHV-A59 and -JHM spike (MHV-
1/SA59 and MHV-1/SJHM, respectively). Isolates were plaque purified, and expanded. 
Figure 5 shows the plaque size comparisons between MHV-1, MHV-A59, MHV-JHM, 
and the recombinant viruses.  MHV-1/SJHM produced plaques similar in size to those 
produced by MHV-1, and thus larger than plaques produced by MHV-JHM.  Plaques 
formed by MHV-1/SA59 recombinants were larger than MHV-1 plaques, with one isolate 
forming plaques similar to MHV-A59 and the other forming plaques intermediary in size 
to MHV-1 and MHV-A59.  We also performed a 24 hour growth curve comparison of 
the recombinants and the MHV spike donors (Figure 6).  We found that the recombinant 
viruses grew similarly to MHV-1 in cell culture assays. 
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Figure 5.  Plaque size comparisons of MHV-1, MHV-59, MHV-JHM, MHV-1/SMHV-
A59, and MHV-1/SMHV-JHM.  Targeted recombination reactions were used to generate 
MHV-1/SMHV-A59 and MHV-1/SMHV-JHM recombinants.  Isolates were plaque 
purified and plaques were selected and expanded.  Plague size was compared to the 
background MHV-1 and the spike MHV-A59 and MHV-JHM donors to verify 
phenotype in cell culture.  
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Figure 6. 24 hour growth curves of MHV-1 and MHV-1/S recombinants.  A. 
rMHV-1/SA59 viruses grew to a similar end point titer and with similar kinetics to 
MHV-1.  MHV-A59 had a higher end point titer than the recombinants. B.  rMHV-
1/SJHM viruses grew to a similar endpoint titer and with similar kinetics to MHV-1. 
 
 
 
A
B
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To determine the effect of the spike protein on respiratory pathogenesis mice 
were infected with MHV-1 (P3) and MHV-1/S recombinant viruses.  Mouse weight and 
oxygen saturation was recorded daily.  Oxygen saturation was measured using the 
MouseOx pulse oximeter.   Clinical scores were also taken for each mouse based on 
movement, appearance, and if breathing appeared labored.  Mice that were infected with 
MHV-1 had both weight loss of 20% or greater and had oxygen saturation decrease to 
80%, and so were euthanized.  The mice infected with MHV-1 had a modified LD50 of 
approximatley 15,000pfu.  Weight loss in mice infected with the MHV-1/S recombinant 
viruses was limited, no more that 5% in any group, and quickly resolved by day 4.  No 
deaths were observed in any of the mice infected with recombinant virus (data not 
shown).  Mice infected with recombinant viruses also did not suffer any decrease in 
oxygen saturation (data not shown).   
MHV-1 5a* 
Because none of the mice that were infected with any recombinant virus suffered 
anything more than transient weight loss we decided to focus on the MHV-1/SMHV-1 
virus.  We considered the possibility that the coding mutation in 5a might be affecting 
pathogenesis and be responsible for the attenuated phenotype.  A recent publication 
demonstrated that the 5a gene might have an important role in pathogenesis by 
functioning as an interferon antagonist (74).   
We generated a  recombinant MHV-1 5a*, which had the 5a coding mutation 
corrected to the native (Genbank Accession FJ647223.1) sequence, reasoning that the 
coding mutation might have eliminated or impaired the function of the 5a protein.    
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Plaque size data showed that most of the recombinants had essentially identical plaque 
phenotypes as MHV-1 (Figure 7A).  The MHV-1 5a* B2 isolate produced smaller 
plaques in this assay, but not in a later plaque size comparison.  A comparison of the 
viruses’ growth kinetics showed that MHV-1 5a*A2 reached titers that were not 
significantly different than that of MHV-1 (Figure 7B).  We considered that these 
changes in in vitro phenotype might have an effect on pathogenesis in mice and moved 
on to mouse infection studies.  
We decided to test the MHV-1 5a* mutant in mouse challenge experiments 
because of the recent publication that demonstrated the importance of a functioning 5a in 
interferon antagonism (74).  However, infection with MHV-15a* resulted in no mortality 
in 6 week old A/J mice, where infection of MHV-1 (P3) at the same doses resulted in 
mortality of at 75% at 10,000pfu and 100% mortality at 25,000pfu (Figure 8).  Despite 
the minor difference in growth kinetics for A2 and the difference in plaque size for 
isolate B5 there were no differences in morbidity or mortality in the infected mice.       
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Figure 7. Plaque size comparison and 25 hour growth curve comparison of MHV-1 
and MHV-1 5a* and NC recombinant viruses.  A. Plaque size comparison of MHV-
1 and the 5a mutation fix and recombinants only containing the AvrII insert and 
elimination mutations, BsmBI elimination mutations, SbfI insert mutation, and the 
G-base deletion.  Only one isolate of the 5a* is significantly smaller than MHV-1.  
B. 24 hour growth kinetic comparison of MHV-1 and the recombinant viruses.  
MHV-1 Silent A6 and MHV-1 5a* B2 both have end point titers that are 
significantly less than MHV-1.   
B
A
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Figure 8. Survival plot of 6 week old female A/J mice infected with MHV-1 or 
MHV-1 5a* recombinants.  Mice infected with the MHV-15a* recombinant show 
no mortality compared to the MHV-1 infected mice.   
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MHV-1/SMHV-1 Non-coding Mut 
 Because the return of the 5a coding mutation to native sequence did not result 
in an increase, or any, mortality in mice this led us to question if the non-coding 
mutations were causing a loss of pathogenicity.  However it is unclear which mechanism 
a non-coding mutation that utilized a codon with equivalent usage statistics in the mouse 
would affect pathogenesis if there were no major differences in plaque size or growth 
kinetics in at least one of the isolates.  We decided examine the plaque isolates that 
contained only silent mutations introduced to generate an isogenic control virus for the 
targeted recombination system.  These mutations were an AvrII site introduction 
mutation (TT23911-12CC,), an AvrII site elimination mutation (AAGA27253-
56TAGG,), two BsmBI site elimination mutations (T24901A; G25069A), a SbfI site 
introduction mutation (CTCCT27981-85GCACC), and a G deletion (27977) that 
occurred during the introduction of the SbfI site because they allow us to manipulate the 
plasmid and exchange the spike region by restriction digestion (All positions relative to 
NCBI FJ647223.1).   
 We used the MHV-1NC virus.  Figure 9 shows that MHV-1NC is not 
significantly different from MHV-1 in its in vitro growth properties.  The 24 hour 
growth curve comparison showed that the kinetics of growth were generally similar with 
one of the recombinants  having a statistically significant lower titer than non-
recombinant MHV-1 at the 24 hour time point due to a drop in titer between 16 and 24 
hours post infection  (Figure 9B). 
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Figure 9. Plaque size 24 hour growth curve comparison of MHV-1 and MHV-1NC 
recombinants. A. Plaque size comparisons of MHV-1 and MHV-1NC show no 
significant difference between the isolates and the wild type virus. B. 24 hour 
growth curve shows that the growth kinetics are not significantly different, but that 
A6 has a statistically significantly a lower end point titer than MHV-1.  
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Figure 10. Survival plot of 6 week old female A/J mice infected with MHV-1 or 
MHV-1/S recombinants. None of the mouse groups infected with recombinant virus 
suffered any mortality. 
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Mice were infected at 6 weeks old with 10, 20, and 30,000pfu of the MHV-1NC 
isolates.  We chose to challenge some mice with a higher dose of virus, 30,000 PFU 
because our previous experiments had shown no mortality and limited morbidity, with 
our recombinant MHV-1NC virus.  Again, groups of mice that were infected with the 
MHV-1NC isolates had no mortalities and only limited weight loss of no more than 5% 
(Figure 10 and data not shown).  They also had no loss in oxygen saturation (data not 
shown).  This data is consistent with the idea that the non-coding mutations are having 
an effect on pathogenesis.  
The non-coding mutations had been selected so that they would not use 
uncommon or infrequently used codons.  Most mutations used a codon with a higher 
frequency of usage in the mouse.  This left RNA secondary structure as a potential cause 
of loss of virulence. We decided to evaluate the non-coding mutations’ effect on RNA 
folding, as our lab, and others,  have established that RNA folding can have an important 
role in virus replication (67, 108, 160, 168).  Table 6 shows the effects of the non-coding 
mutations on folding ΔG.  We used multiple algorithms to generate the ΔG and 
calculated the average ΔG.  We determined that it was unlikely that the AvrII site 
introduction mutation had any effects, as there we no change in folding energy.  This is 
also supported by other MHV targeted recombination systems that introduced an AvrII 
site at the same location to facilitate spike swaps, with no effect on the virulence of 
otherwise isogenic recombinant viruses (58).  It was noticed that the largest effect on ΔG  
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Figure 11. Mfold predictions of RNA secondary structures.  A. MHV-1 structure 
prediction of the region of spike containing the two native BsmBI sites.  B. 
Recombinant MHV-1NC structure prediction of the region of spike containing the 
mutations used to eliminate the BsmBI sites.  The mutations introduced to 
eliminate the BsmBI sites appear to destabilize a stem structure as well as alter a 
side loop on the left side of the stem. 
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Table 6.ΔG Calculations on the regions of the genome containing known mutations 
introduced by targeted recombination in the generation of MHV-1/S viruses.  
Mutations  
Difference in ΔG (Mut-WT) 
MFE*  TE% VC# CF@ mFold& 
Average 
Difference 
AvrII 
Intro 0 0 0 0 0 0 
BsmBI 
Elims  6.3 6.21 29.05 24.5 7.84 14.78 
AvrII 
Elim 2 2.56 12.6 5.88 5.38 5.684 
G deletion 0 2.52 -7.7 -2.5 0.89 -1.358 
E nc mut -1 -1.83 6.69 8.61 2.4 2.974 
*MFE- Minimum Free Energy as calculated by RNAFold Web Server 
%TE- Thermodynamic Ensemble as calculated by RNAFold Web Server 
#VC- Centroid as calculated by RNAFold Web Server 
@CF- Centroid Fold as calculated by ncRNA.org 
&mFold-  mFold as calculated by mFold 
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was the due to the elimination of the BsmBI sites within S and the Mfold generated 
predicted secondary structures for this region of the native MHV-1and recombinant 
MHV-1NC RNA genomes are shown in Figure 11.  The AvrII elimination mutation may 
also have an effect on RNA folding but it was relatively small, but that site had to 
remain in the isogenic control to permit subsequent use of the introduced AvrII sites in 
excision of the MHV-1 spike and the replacement of the MHV-1 spike with MHV-A59 
or –JHM spikes, which was done above.   
MHV-1/SMHV-1 AvrII  
We reconsidered our strategy regarding the absolute requirements for an 
appropriate isogenic control virus.  Because of the potential effects the BsmBI mutations 
had on RNA folding we decided to return those sites to the native sequence.  We thus 
utilized targeted recombination to generate the MHV-1/SMHV-1 AvrII virus. This left us 
with a virus that contained only the AvrII introduction mutation, the AvrII deletion 
mutation, and the SbfI introduction mutation.  Those mutations were required to remain 
because they were vital for the restriction enzyme swaps that were necessary to insert in 
the spike genes from MHV-A59 and –JHM.  Because previous plaque size comparisons 
and growth kinetic data revealed no differences from wild type for the MHV-1NC virus, 
we decided to move directly into mouse studies with the MHV-1/SMHV-1 AvrII virus.     
MHV-1 Loses Virulence during Passage in DBT 
Our previous experiments had exhausted our supply of the wild type MHV-1 P3 
virus, thus necessitating the growth of a new MHV-1 stock to use as a control virus in  
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Figure 12. Percent weight gain of 6 week old female A/J mice infected with the 
calculated LD50 of MHV-1P4 and an equal amount of MHV-1 AvrII virus. None of 
the mice suffered severe weight loss nor mortality.  Most of the weight loss is not 
significantly different between the two viruses used.  
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our experiments of MHV-1 AvrII.  This new stock, a passage 4 virus generated from the 
P3 virus used in our previous experiments was used in a mouse challenge experiment 
(Figure 12).  15,000pfu was the LD50 established for MHV-1 P3 used in prior 
experiments.  Mice were infected at 15,000pfu with MHV-1 or MHV-1AvrII.  
Surprisingly neither virus caused dramatic weight loss or any mortality. 
With the attenuated phenotype of the new passage of MHV-1 we decided to 
increase the dose we used to infect mice, as well as generate a new P3 virus from the 
original seed stock of P2 virus in case this was a variance due to passage.  We also 
increased the infecting dose to 25,000pfu, or 2x the LD50 of our original P3 stock used 
for prior experiments (Figure 13A).  Both of these viruses failed to produce mortality at 
this challenge dose.  We considered that the problem may be due to the mice.  We 
considered that the acclimation time might be affecting the immune response to the 
MHV-1 infection, and since the pathogenesis is considered immune mediated then 
anything that might affect the immune response (ie travel stress or poor acclimation) 
would affect mortality.  We held the mice for one week prior to infection, making them 
7 weeks old at the time of infection, and used the 2x LD50 and the same virus as in the 
previous experiment (Figure 13B).  This also failed to produce any mortalities so we 
considered that there may be something affecting the mice local to our supplier.  While 
NCI labs did not report any positive tests for MHV during the period we obtained mice 
for our most recent experiments, we ordered mice from Jackson labs, and asked the 
Weiss lab to order NCI mice, since we established that the Weiss lab mice came from a 
different breeding location at NCI.  The mice were held at our lab, and at the Weiss lab, 
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for 4 days and were infected with 2x LD50.  The MHV-1 that was used was the same 
passage level, 3, but had been passaged, independently in the two labs.  Both stocks were 
derived from the same vial of virus in the Leibowitz lab, where MHV-1 was obtained 
from the ATCC, was plaque purified and passaged to P2 at which time the P2 was sent 
to the Weiss lab and the Levy lab in approximately 2004.  Figure 13C shows that our P3 
stock inoculated into 6 week old A/J females from Jackson labs still failed to produce the 
expected mortality. The Weiss lab, with their independently passaged P3, also had no 
deaths in their experiment (data not shown).  After this result we considered that we may 
need to increase the infecting dose as well as lower the age of the animals.  Other studies 
have shown that age of the mice affects mortality rates and mice as young as 5 weeks 
have shown to be susceptible to MHV-1 infection (22, 71).  We infected 5 week old A/J 
female mice, from NCI, with 30- and 90,000 pfu.  There was no mortality and mice did 
not lose more than 8% of their starting weight (Figure 13).   
Because of these experiments we decided to obtain a known virulent passage of 
MHV-1.  We obtained a virulent MHV-1, P3, from the Levy lab.  As stated earlier the 
Levy lab obtained their MHV-1 stocks from our lab many years ago.  This P3 was 
generated independently in 17Cl-1 and had been used in previously published work (3).  
We noted that the LD50 reported by the Levy lab, 2.4 x102, was significantly lower than 
our experimentally determined LD50, 1.5x104, for our original P3 virus.  We did a 
plaque size comparison of this virus (MHV-1 GAL) to our recombinant MHV-1/S AvrII 
and to our avirulent MHV-1 (Figure 14).  Although the mean plaque diameter for MHV-  
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Figure 13. Percent weight gain of female A/J mice infected with P3.2 of MHV-1 
using different acclamation times and different doses. A. Infection of mice a 
2xLD50 that was originally calculated for MHV-1 using MHV-1 P3.  B. 2xLD50 
and mice were held for 1 week and were 7 weeks old at the time of infection with 
MHV-1 P3.2.  C. Mice from different supplier, Jackson Laboratories, were infected 
with 2xLD50 with MHV-1 P3.2.  D. 5 week old mice were infected with 30 and 
90,000 pfu of MHV-1 P3.2 only.  
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Figure 14. Plaque size comparison of a virulent virus, provided by the Levy Lab 
(P3), the Leibowitz lab MHV-1 (P3.2).  MHV-1GAL produces larger plaques than 
MHV-1 or MHV-1 AvrII, but only MHV-1 plaque sizes are significantly different 
in size.   
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Figure 15.  Mortality curve of mice infected with MHV-1 P3.3 (32500pfu) or MHV-
1 GAL P3 (8300pfu).  The MHV-1 GAL virus caused 100% mortality by day 4, 
while the MHV-1 virus had above 50% mortality at 32500pfu.   
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1 GAL is larger than that of our two viruses, this difference is not statistically significant 
for MHV-1 GAL and MHV-1AvrII. However there is a statistically significant 
difference between MHV-1GAL and our avirulent MHV-1 P3.2.  The biological 
significance of this difference was not further investigated.   
We then grew a new P3.3 virus stock and mice were infected with this new 
MHV-1 P3.3, at 32500pfu or MHV-1 GAL P3 at 8300pfu. The Levy virus was highly 
virulent producing 100% mortality by day 4 post infection.  The new P3.3 stock that we 
had grown was also virulent and produced over 50% morality at 32,000pfu.  We 
considered the difference in LD50 was likely due to natural variance between generated 
stocks.  Our lab was able to generate a pneumovirulent P3 50% of the time, the Levy lab 
had a pneumovirulent P3, and the Weiss lab had an avirulent P3.  This caused us to 
reconsider the use of MHV-1 at a 3rd passage for future experiments and we considered 
going back further into our stocks to generate lower passage virus stocks.    
DISCUSSION 
Our lab started with a plasmid with known mutations that was used to generate 
recombinant virus in the hopes of developing a targeted recombination system for MHV-
1.  Our initial isogenic control recombinant virus was severely attenuated and produced 
no mortality in contrast to our original P3 stock of MHV-1.  We attempted to identify 
mutations to account for the attenuated phenotype that we were seeing in our 
recombinant isogenic control viruses.  However, once we corrected the previously 
discounted coding mutation in ns5a and this did not affect the virulence of the 
recombinant virus, we had to resort to changing non-coding mutations that may have 
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effected RNA folding.  We hypothesized that if RNA folding was dramatically effected 
that it might negatively impact the ability of the virus to utilize its’ native interferon 
antagonsists and RNA masking methods.  However, even upon return of the native 
sequences in regions that were most likely negatively effecting RNA folding we still did 
not recover recombinant viruses with a virulence similar to that of MHV-1.   
These results, taken together, do pose a unique question: what is causing the loss of 
virulence in MHV-1?  We have tested multiple 3rd passages of MHV-1, all 
independently generated, and had widely divergent LD50s, and in some cases none, for 
each.  The MHV-1GAL virus had the lowest LD50, while P3 viruses (P3, P3.2, P3.3) 
generated in our laboratory varied from an LD50 of 15,000pfu to an LD50 which could 
not be determined, but was higher than 90,000pfu.  The Weiss lab also generated a 
MHV-1 P3 that was not lethal at 25,000pfu.  Based on published records we know that 
both the Leibowitz lab and the Weiss lab passage MHV-1 in DBT cells, whereas the 
Levy lab reports that they use 17Cl-1 cells for their MHV-1 propagation.  While it is 
possible that the cell lines used for propagation may affect the viruses’ maintenance of 
virulence genes it would be easier to look for possible genetic contributions of virulence.   
Most importantly the loss of virulence in our MHV-1 over only 3 passages points 
to the fact that the targeted recombination system will not be viable for generating 
pneumopathogenic MHV-1 recombinant viruses.  We can easily generate recombinant 
virus that is not significantly different from MHV-1 in tissue culture, however if the 
virus is going to be used in pathogenesis studies then targeted recombination may not be 
a viable method for genertating recombinant virus.  Targeted recombination requires too 
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many passages in cell culture.  The process of targeted recombination requires the use of 
a feline spike-MHV-1 that was generated by targeted recombination, was passaged, 
plaque purified, and expanded through multiple passages. This high-passage fMHV-1 is 
used to generate the desired recombinant MHV-1 which is, again, passaged multiple 
times, plaque purified, and then expanded into multiple passages.   
Other strains of MHV have not shown significant attenuation when passaged 
multiple times in cell culture.  We have utilized MHV-JHM P4 with no significant loss 
in neurovirulence, and MHV-A59 and MHV-3 P3 stocks with no significant loss in 
expected pathogenicity in the liver.  We do not know for certain what the passage level 
of MHV-1 was used to generate the fMHV-1 virus.  It is likely that the MHV-1 P3 or 
perhaps even a higher passage stock was used.If the P3 virus was used it was most 
probably  done with the MHV-1 P3 from the Weiss lab which we have shown to be 
avirulent in the lung infection of A/J mice. The Weiss lab’s MHV-1 P3 was also the 
virus that was used to generate the virus that was sequenced by the TIGR lab and the 
sequence was submitted to GenBank (FJ647223.1).  We also cannot say for certain that 
targeted recombination can never be used to generate a pneumopathogenic virus, 
however our data show that it will be challenging to do so if pneumovirulence cannot be 
stably maintained over multiple passages.     
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CHAPTER IV 
WHOLE GENOME SEQUENCING OF AN AVIRULENT AND VIRULENT 
PASSAGE OF MHV-1 SHOW DIFFERENCES IN VARIANT POPULATION 
 
INTRODUCTION 
Severe acute respiratory syndrome coronavirus (SARS-CoV) is a novel human 
coronavirus that caused the first major pandemic of the new millennium in 2002-2003 
(150).  The more recent 2012 emergence of the Middle East respiratory syndrome 
coronavirus show a continuing need for animal models of severe coronavirus disease (5, 
62, 97).  Animal models for SARS-CoV include civet cats, Syrian hamsters, non-human 
primates, rats, and mice (82, 85, 100, 101, 127).  Another animal model involving MHV-
1 in A/J mice has been shown to be a viable model of SARS-CoV disease (3).  There are 
multiple advantages to the MHV-1 model of SARS-CoV infection: 1) MHV-1 can be 
safely worked with in BL-2 facilities, 2) there is no concern of human respiratory 
infection with MHV-1, 3) working with MHV-1 in mice at a BL2 facility is less 
expensive than working with SARS- or SARS-like- CoV in a BL3 lab.  
MHV-1 infection of A/J mice produces pathologic changes in the lung which 
include progressive interstitial pneumonitis, including dense macrophage infiltrates, 
giant cells, and hyaline membranes (3), changes which are similar to the histopathology 
seen in human infections with the closely related SARS-coronavirus (106, 111).  
Infection of A/J mice with MHV-1 also results in death of animals, where other strains 
of mice developed less severe and transitory disease, which facilitates end points of 
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study (3).  A/J mice also have similar cytokine and chemokine responses as those seen in 
SARS-CoV infected patients (65).     
There is indication that the SARS-associated coronaviruses have been 
evolutionary independent for a period of time prior to the outbreak (64, 121). While 
SARS-CoV is considered as a single genomic entity, there are several studies that 
indicate that SARS and SARS-associated coronaviruses maintain a quasispecies (64, 
141).  During the epidemic, different strains were being identified and had potential 
effects on patient health and survival (144).  Studies have demonstrated the presence of 
multiple quasispecies of SARS-CoV in an individual patient (142, 166).   The exact role 
of quasispecies in SARS-CoV infection and pathogenesis is unclear.  Coronaviruses do 
have a mechanism to recognize and correct mutations that arise during genome 
replication, nsp14 (32).  The presence of this exonuclease lead to reasoning that assumed 
that coronaviruses did not utilize the mechanisms of quasispecies diversity to the extent 
that other RNA viruses did.  The reports of quasispecies in patients and our findings in 
MHV-1 infection and pathogenesis support the hypothesis that quasispecies may play an 
important role in pathogensis.    
Studies have evaluated the presence of quasispecies in patients, but none to date 
have evaluated if there is a correlation between quasispecies and clinical disease or 
outcome.  One study evaluated the full-length spike glycoprotein of SARS-associated 
coronavirus from 19 hospitalized patients and found a total of 107 sequence variations 
with 9 recurrent variant sites in the S gene of the BJ01 strain (166).  In 7 of the 19 
subjects researchers found the coexistence of two variants, and one patient had three 
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variants. Researchers also found that the population variants would change over time, as 
samples collected from the same patient would show similar, but not identical, variant 
profiles.  Another study found evidence of heterogeneous populations of subgenomic 
RNA 3 in patients with acute SARS-CoV infections (142).  Looking at a T track repeat 
in SARS-CoV gene 3a they found different in T repeats between six and ten.  In 6 of the 
8 patients had viral populations with either 6 or 9T’s, meaning a full length 3a, or with 
one additional amino acid, would be generated.  Most patients only had two populations 
of T repeats: three with 6/7, one with 8/9, and one with 7/10.  Two patients had 
homogeneous populations with 6 T’s and one patient had three populations of T repeats, 
seven to 9 repeats.  Vignuzzi et al show that quasispecies diversity is important in 
pathogenesis in a neuroinvasive polio virus model (156).  They demonstrate that virus 
pathogenicity is decreased by a mutation in the polymerase, which causes enhanced 
fidelity and reduces virus sequence diversity.  Viruses with the high fidelity polymerase 
show a reduction in total number of mutations per nucleotides sequenced and show a 
reduced number of mutations per genome.  Viruses with enhanced fidelity are also less 
neuropathogenic and are less able to invade other tissues in a mouse infection.  This 
paper supports the idea that quasispecies diversity is important in pathogenesis, though if 
this relates to coronavirus infection is not yet known.     
 
 
 
 
 92 
 
RESULTS 
Loss of Pneumovirulence in MHV-1 during Passage in Cell Culture 
We investigated the reason that MHV-1 does not maintain pneumovirulence over 
serial passages in cell culture.    Figure 16 shows the history of our MHV-1 viral stocks 
and the generation of our stocks used in this study.  We used the same P2 stock to to 
generate both virulent P3.3 virus, an avirulent P3.2 virus, that was used in the previous 
chapter (Figure 14) in sufficient quantities to sequence.  We retrived freezer stocks and 
used the P1 stock, a stock that is the parent to all of our MHV-1 stocks including the 
avirulent and P3 stocks described above, and we used this to generate a large P2.2 stock 
sufficient for sequencing.  Both stocks were tested in mice to determine if they did or did 
not cause mortality or loss of lung function (Figure 17 and 18).  We used avirulent P3.2 
and a virulent P2.2 MHV-1 stock to attempt to identify any dominant mutations or any 
change in subspecies populations.  No dominant population mutations were found, but 
there were subpopulation variances between the virulent virus and the avirulent virus.  
The dominant consensus sequence was identical to the sequences in Genbank, which 
include Genbank Accession  FJ647223.1 which covers the entire genome, with the 
exception of the extreme  5’ end of the MHV-1 genome, which is covered in a separate 
Genbank entry, Accession EF682499.1.  These two sequences were combined to create a 
reference sequence that our lab used to compare the virulent and avirulent sequencing 
results.     
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ATCC MHV-1 lyophalized tissue sample was rehydrated and passed into DBT 
 
Virus was plaque purified 
 
P1 
 
                              P2      P2.2 (Sequenced) 
 
 
               P3- virulent stock for study   P3.2- Avirulent   P3.3-Virulent 
   (Chapter 3)     (Sequenced) 
 
P4- avirulent 
 
Figure 16. Flow chart showing the generation of MHV-1 passages.  The lab 
purchased MHV-1 from the ATCC collection and received a sample as a 
lyophilized tissue sample.  The sample was hydrated and passaged into DBT cells.  
The resulting virus was plaque purified and passed to generate P1.  P1 was 
expanded into the original P2 and P3.  The original P2 virus was later given to the 
Weiss and Levy lab groups and was used as our original stock in mouse studies.  
When we exhausted our P3 we generated a P4, which was avirulent.  We went back 
to a P2 and generated P3.2, which was also avirulent.  We went back to P1 and 
generated a P2.2 stock that was pneumovirulent.  
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Figure 17. Percent weight gain in mice infected with P3.3 virus used in whole 
genome sequencing. Female A/J mice, 6 weeks old, were infected with 30,000pfu 
MHV-1 P3.  Mice lost no more than 8% of their starting weight and there was no 
mortality or loss of lung function.   
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Figure 18. Percent weight gain and Percent survival of mice infected with MHV-1 
P2.2 used in whole genome sequencing. A. Percent weight gain in Female A/J mice, 
6 weeks old, infected with MHV-1 P2.    The increase in weight after day 4 is 
primarily due to the one mouse that survived the challenge. (see Panel B) B.  
Percent survival of female A/J mice, 6 weeks old, infected with MHV-1 P2.   Mice 
infected with 5,000 or 10,000pfu of MHV-1 P2.  Because we expected P2 to be 
virulent we chose to use a lower infectious dose.  Mice infected with 10,000pfu lost 
weight rapidly and all mice were dead by day 5.  Mice infected with 5,000pfu also 
lost weight, and had 80% mortality. 
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Avirulent Virus Whole Genome Sequencing 
  The avirulent P3 virus containing cell culture supernant was purified by density 
gradient centrifugation as described in Materials and Methods and RNA was extracted 
and used to generate cDNA.  We used random primers that our lab had used previously 
in whole genome sequencing (167).  To avoid gaps and to ensure adequate coverage of 
the 5’end we also used specific MHV-1 primers (see Materials and Methods) because in 
our previous experience with whole genome sequencing there were gaps that had to be 
filled by amplifying specific regions by RT-PCR followed by additional Sanger 
sequencing reactions.   
 We used the CLC Genomics Workbench (version 6.5.1) to align the shotgun 
sequences of the avirulent virus to the MHV-1 reference sequence that was generated 
using the MHV-1 genome reported in NCBI (FJ647223.1) combined with the 5’ leader 
sequence that our lab reported to NCBI (EF682499.1).  We note that the NCBI MHV-1 
genome (FJ647223.1) is, we believe, the sequence of an avirulent virus.  TIGR 
sequenced a virus given to them by the Weiss lab, a virus passage we now know to be 
avirulent.   
Our sequencing run of the avirulent virus yielded 4988704 individual reads and 
66% of them aligned to our reference sequence. Figure 20 shows the sequence coverage 
map that was generated with the avirulent sequence when aligned to the reference 
sequence, showing no gaps in coverage.  
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Figure 19. Coverage of MHV-1 genome, NCBI database, by shotgun sequencing the 
genome of an Avirulent MHV-1 P3 virus passage.  The three curves show the 
maximum (dark blue), mean (blue) and minimum (light blue) read coverage value 
observed in a given region of the genome.  
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Table 7. List of avirulent virus genome variants at 2% 
Base position* Variant Frequency Gene location 
59 Insertion AATCT 2.51 5’ UTR 
59 AATCT deletion 4.48 5’UTR 
11587 C->T 2.26 nsp6 
15323 Insertion G 2.55 nsp12 
17040 C->A 12.39 nsp13 
17442 TT->AG 4.01 nsp13 
19435 T->C 2.19 nsp14 
23343 T->C 2.04 HE 
23816 A->G 7.5 HE 
24337 G->A 4.32 Spike 
28479 G->A 2.4 Ns4 
29048 A->T 2.4 Membrane 
*Genome position is based on the combination of MHV-1 genome (FJ647223.1), which 
is 25 nucleotides short of the true 5’ terminus, and the 5’UTR containing sequence 
(EF682499.1) which extends to the true 5’ end of the genome.  To calculate the base 
position in the MHV-1 genome (FJ647223.1) subtract 25 from the listed base position.   
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Because alignment of the avirulent shotgun sequences with the MHV-1 genome 
showed no deviations of the consensus sequence from the MHV-1 reference sequence 
we used the CLC genomics workbench to look for variants in the sequence population.  
We ran thresholds for variant populations at 10% and then at 5% in the hopes of finding 
multiple variant populations.  At 5% we found two subpopulations, one in HE and one in 
nsp13.  The variant in HE was present at 7.5% in the avirulent population and was 
present at a lower percent in the virulent virus (2.32%, see section below).  The second 
variant was in nsp13 and was present at 12.39% in the avirulent population, but was 
present at a higher percent in the virulent population (19.1%, see section below). 
Because the error rate of the Illumina Hi-Seq is published at 1.18% we decided to lower 
our threshold and look for population variants at 2%.   
When we aligned the avirulent reads to the reference and tested the population 
for variance at 2% we found that the avirulent population contained 12 variants (Table 
7).  Of these variants only three prove to be unique to the avirulent passage and all were 
less than 5% in frequency.  One variant was in the S protein, one was in HE downstream 
of the stop codons, and the final variant was present in ORF1a.  We decided not to look 
for population variants less than 2% because we did not want to risk finding populations 
that were effect by sequencing errors.   
 
 
 
 100 
 
 
 
Figure 20. Coverage of MHV-1 genome, NCBI database, by shotgun sequencing the 
genome of a virulent MHV-1 P2 virus passage.  The three curves show the 
maximum (dark blue), mean (blue) and minimum (light blue) read coverage value 
observed in a given region of the genome.  
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Table 8. List of virulent virus genome variants at 2% 
Genome position* Variant Frequency Gene location 
8 A->G 7.69 5’UTR 
12 A->T 3.57 5’ UTR 
14 Insertion A 2.38 5’ UTR 
59 Insertion AATCT 2.82 5’ UTR 
59 AATCT deletion 3.76 5’ UTR 
73 T->C 2.00 5’ UTR 
1097 A->G 2.85 nsp2 
3883 T->A 2.12 nsp3 
15323 Insertion G 2.63 nsp12 
17040 C->A 19.10 nsp13 
17442 TT->AG 2.84 nsp13 
19435 T->C 2.2 nsp14 
22695 T->C 2.01 HE 
22701 G->T 2.52 HE 
23758 G->A 2.74 HE 
23816 A->G 2.32 HE 
28479 G->A 10.89 Ns4 
29048 A->T 3.7 Membrane 
* Genome position is based on the combination of MHV-1 genome (FJ647223.1), which 
is 25 nucleotides short of the true 5’ terminus, and the 5’UTR containing sequence 
(EF682499.1) which extends to the true 5’ end of the genome.  To calculate the base 
position in the MHV-1 genome (FJ647223.1) subtract 25 from the listed base position.   
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Virulent Virus Whole Genome Sequencing 
We generated a new passage 2 (P2.2) stock of MHV-1 in a quantity sufficient for 
both mouse experiments and for whole genome sequencing (Figure 16).  We tested this 
virus in 6 week old A/J female mice and found it to be more virulent that our original 
virulent MHV-1 P3 (Figure 19B).  We did not calculate an actual LD50 for this virus.  
80% of the mice that were infected with 5,000pfu died, so we can conclude that the 
actual LD50 of this virulent P2 is less than 5,000 pfu, which is an amount lower than that 
of our P3 virulent virus.  This is also interesting because this P2 virulent virus is more 
like the MHV-1GAL virus from Dr. Levy’s lab in its LD50.  This may support the idea 
that passaging of the virus resulted in loss of a subspecies that helps generate a 
pathogenic virus phenotype.    
Virulent P2 virus was purified and cDNA prepared in the same way as for the 
avirulent virus.  Both random and specific primers were used to generate cDNA for 
sequencing.  The yield of cDNA template available for sequencing was similar to that 
obtained from the avirulent P3 virus.  The sequencing run resulted in a total of 
15,197,732 reads, which was more than double the number of reads we got for the 
avirulent sequencing run.  However, only 5.5% of the reads from the virulent sequencing 
results mapped to our reference sequence, though coverage still extended over the entire 
genome, with greater than 10x coverage being achieved (Figure 21).  The decrease in 
reads that map to the MHV-1 reference sequence is likely due to the presence of a 
substantial amount of ribosomes entrapped with membrane fragments copurifying with 
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this virus preparation.  There was also a large quantity of mycoplasma DNA segments 
present in the sample.       
We aligned the virulent virus reads with the reference sequence, described above.   
Using CLC Genomics Workbench we found that again there were no difference in the 
consensus sequence between the virulent MHV-1 P2 and the MHV-1 reference 
sequence.  We also tested this sequence for population variants using a 10% and 5% 
threshold.  We found one sequence subpopulation with a point mutation in ns4 and one 
sequence change from the reference sequence in nsp13, both were present at a higher 
frequency in the virulent virus than the avirulent virus.   
When we aligned the virulent virus reads to the reference and tested the 
population for variance at 2% we found that the virulent passage had 18 variants, 9 that 
were conserved between the avirulent and virulent viruses (Table 8).  Of the 9 variants 
conserved between the two passages only one differed by more than 5% (5.18%) 
between the virulent and avirulent viruses, where the rest had frequency differences of 
less than 5%.  Of the 9 variants that were unique to the virulent passage four were in the 
5’ UTR between bases 8 and 73 of the complete genome, mapping to sequences 
contained inthe 5’ Leader (EF682499.1).  These mutations might affect the structure of 
the 5’UTR region and may affect replication, as our lab has demonstrated that 5’ UTR 
structures can play an important role in betacoronavirus replication (67, 168).  However, 
our initial analysis shows that of these variants only the variant at base position 12 might 
have a significant effect on RNA folding, and that effect would likely be to destabilize  
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Table 9. Common variants and population percentages between P3 Avirulent and 
P2 virulent virus sequences above 10% 
MHV-1 passage Mutation*/ % of 
population 
Gene location Potential effects 
P3(Avirulent) C17040A/12.39% Nsp13 A237D,  affects 
conserved A, but 
not a known 
structure (63) 
G28479A /2.4% Ns4 A133T, affects 
predicted helix 
structure at c-
terminus 
P2(Virulent) C17040A/19.1% Nsp13 A237D, affects 
conserved A, but 
not a known 
structure (63) 
G28479A/10.89% Ns4 A133T, affects 
predicted helix 
structure at c-
terminus 
*Variant base position is based on the MHV-1 reference sequence: a combination of 
MHV-1 genome (FJ647223.1), which is 25 nucleotides short of the true 5’ terminus, and 
the 5’UTR containing sequence (EF682499.1) which extends to the true 5’ end of the 
genome.  To calculate the base position in the MHV-1 genome (FJ647223.1) subtract 25 
from the listed base position.   
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the stem of SL1.  The remaining three are unlikely to have any major effect on RNA 
folding and downstream virus replication due to effects on the 5’UTR structures.  There 
were three unique variants that mapped to the HE gene, two of which would affect the 
truncated HE protein, should that protein be produced. It should be noted that for MHV-
1 the subgenomic mRNA that encodes the HE is present at undetectable levels, if at all 
(83, 170). The third variant occurs after the six stop codons and so is unlikely to have an 
effect on any protein or structure.   
Differences in Population Variants between Virulent and Avirulent Viruses 
Comparing the population variants, both the avirulent and the virulent viruses 
have a conserved subpopulation present in the 5’UTR (ACTCT deletion and insertions), 
in nsp13 (17040), in HE (23816), in ns4 (28479), and in M (29048).  Only the nsp13 and 
ns4 varaints have values higher than 5%, so we will concentrate on those two (Table 9).  
The avirulent virus has fewer unique variants, three, whereas the virulent virus has more 
variants that are unique, nine.  Both viruses have a subpopulation of mutations in nsp13 
compared to the reference sequence in NCBI. It should be emphasized that we do not 
know if the virus sequenced by TIGR was virulent or avirulent but is was derived from 
the original virulent P2 stock that we provided to the Weiss lab.  The percent of 
C17015A sequence reads is 12% in the avirulent virus and is 19% in the virulent 
population, suggesting that the population containing this mutation may play a role in 
pathogenesis.  The C17015A mutation is a coding mutation that produces an A237D 
change in the nsp13 protein sequence and is predicted to affect a helical structure in the 
protein.  The helix containing the mutation is not part of a known enzymatically active 
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site or a structural domain with known biochemical function, it is located in the spacer 
region between the zinc binding domain and the active sites present at the carboxyl end 
of the protein (63).  The avirulent virus has an A23791G mutation that is present in 7.5% 
of the population that causes a noncoding mutation in the HE gene.  The mutation occurs 
after the three stop genes that cause HE to be a pseudogene in MHV-1 so the role of this 
mutation, if any, is unknown.  Most interestingly is the G28454A mutation that occurs in 
ns4 in the virulent strain.  This mutation is results in an A133T amino acid change that 
shortens a predicted helical structure at the c-terminus of the ns4 protein.   
 We screened for these variations by subcloning reverse-transcribed and PCR 
amplified fragments and then using traditional Sanger sequencing to screen the 
subclones.  We were unable to find the ns4 mutation in a P3.2.1 or a P4.2.1, indicating 
that this sequence variant is likely not maintained over passages in cell culture (Table A 
2).  We have also, to date, been unable to find the nsp13 variant in a P3.2.1 or a P4.2.1 
(Table A 1).  We also extracted viral RNA from a mouse lung, post infection day 3, and 
subcloned the nsp13 varaint region, and have also, to date, been unable to find the nsp13 
variant in the screened population.  Admittedly, subcloning is a less sensitive way to 
isolate variants and identify variant populations compared to Hi-Throughput sequencing 
methods used to sequence the whole genome.    
DISCUSSION 
Because there was no dominant polymorphism present in the virulent or avirulent 
genome sequence we used a 10% and 5% threshold we examined the whole genome 
sequencing data for population variants.  We saw that there were nine common variant 
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populations between the virulent and avirulent sequences when compared to the 
reference sequence.  We found that the avirulent virus had only three unique variant 
populations, whereas the virulent virus had nine unique variant populations compared to 
the MHV-1 reference genome.  Of those variant populations the two that stood out the 
most because of their high frequency were the variant population in nsp13 and ns4.  The 
nsp13 is a difference in subpopulation percentage of a coding mutation, which is a 
helicase with multiple enzymatic domains.  While this mutation does affect a helical 
domain, it does not appear to be in a known functional domain so the effect on 
pathogenicity is unknown.  However, in mouse adapted SARS-CoV there is a nsp13 
mutation that is present in both lethal strains (22).  It is a C16177T mutation that causes 
an A5305V alteration in the amino acid sequence.  However, this mutation is at the 
amino terminus of nsp13, whereas our mutation is near the center of the protein and is 
predicted to interrupt and shorten a central helical domain.   The A5305V mutation in 
MA15 does not alter the helical structure at the amino terminus of nsp13.       
The mutation in the ns4 region occurs in almost 11% of the population in the 
virulent strain and is present at 2.4% in the avirulent strain.  This is interesting because 
ns4 has been shown to be dispensable in replication (171).   No function has been 
assigned to ns4 at this time.  It would be novel to show that ns4 plays a role in 
pathogenesis.   
The study evaluating the quasispecies population of SARS-CoV ORF 3a show 
variations of ~5-70% in patient populations with two quasispecies (142).  Since clinical 
outcomes were not reported we cannot hypothesize a correlation between quasispecies 
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and disease in humans.  Our studies indicate that there is a threshold, for certain genes, 
which are present in a virus which causes severe lung disease versus only mild weight 
loss.   
The role of the nsp13 and ns4 sequence variants are not presently clear.  They 
cannot be located when we reverse-transcribe and subclone cDNA.  It is possible that 
these sequence variants need to be present in the infecting population at a certain level, 
that if these mutations are dominant in the population they generate a virus that has a 
very high LD50 and does not generate lung pathology.  We also cannot be sure if these 
mutations occur in the same viruses or are unique mutations in two separate 
subpopulations, meaning we do not know how many quasispecies are involved in the 
virulent virus: two or three. 
The presence of quasispecies in MHV-1 and the rapid tissue culture adaptation 
and attenuation of virulence also means that targeted recombination is not a reliable 
option for genetic manipulation and study of the MHV-1 model of SARS.  We have 
shown above (chapter 3) that LD50 MHV-1 can be dramatically increased by 3 
passages.  The nature of the targeted recombination protocol involves multiple blind 
passages and repetitive passages in cell culture.  This, apparently, causes a loss of 
quasispecies either due to loss of diversity or bottle necking during plaque purification.  
Because of this there will need to be a mechanism in order to be able to maintain the 
necessary mutations or mitigate the loss of quasispecies in cell culture.   
In order to generate and study these mutations we will need to use a complete 
reverse genetic system.  The complete reverse genetic system requires fewer passages in 
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cell culture to generate enough virus to use in animal studies.  Also virus can easily be 
regenerated if more is needed without more passages in cell culture.   
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CHAPTER V  
CURRENT PROJECTS AND FUTURE DIRECTIONS 
 
INTRODUCTION 
Originally coronaviruses were found to cause self-limiting respiratory infections 
and were thought to be species restricted (98, 160, 187).  However, in 2002 a novel 
coronavirus outbreak in  China quickly became the first pandemic of the new 
millennium and changed how scientists thought about coronaviruses and the disease 
causing potential of  these viruses (37, 116, 150, 159, 180).  Though the pandemic ended 
in 2003, there is still a necessity for study of coronaviruses that cause serious human 
respiratory illness.  The recent emergence of Middle Eastern Respiratory Syndrome 
coronavirus (MERS-CoV) shows the continued need for the study of coronavirus disease 
in humans (5, 26, 62, 97).  Currently the animal models that have been used to study 
SARS-CoV, with varying fidelity to the human disease, include primates, Syrian 
hamsters, cats, ferrets, rats and transgenic mice (9, 11, 13, 22, 45, 82, 99, 101, 117, 125, 
127).  These animal models use SARS or SARS-adapted coronaviruses for study of the 
disease.     
The genome of coronaviruses is organized into an ORF1ab region encoding a 
polyprotein which is processed into proteins required for RNA replication and 
transcription, and downstream of this a series of virus-species specific genes mixed in 
with genes that code for structural proteins.  All coronaviruses encode the spike protein 
(S), envelope protein (E), membrane protein (M), and nucleocapsid protein (N), in that 
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order, at the 3’ end of the genome and this is followed by an untranslated region that is 
functionally important (111, 160).  MHV-1 and the pathogenic human 
betacoronaviruses, CoV-HKU1 and HCoV-OC43 contain a hemagglutinin esterase gene 
(HE) but SARS-CoV and other SARS-like-CoV do not.  Coronaviruses also contain 
strain specific non-structural genes, so-called accessory genes, that are interspersed with 
the genes encoding the structural proteins, and these genes often encode proteins that 
modulate or evade host antiviral responses.  These non-structural genes are not critical 
for replication in cell culture (160, 171).  MHV-1 contains genes encoding a viral cyclic 
phosphodiesterase (ns2 (130)), an interferon antagonist (ns5a (74)), as well as ns4, a 
gene that currently has no assigned function (171).   
SARS-CoV is a member of the  betacoronavirus genus, as is MHV, but it is a 
member of betacoronavirus subgroup 2, (72, 139), whereas MHV is a member of 
subgroup 1.  MHV-1 causes a respiratory disease clinically similar to SARS-CoV in six 
week old A/J mice (3).  Although MHV-1 and SARS-CoV, both belong to the 
betacoronavirus genus, they have significant sequence differences, and in particular their 
non-structural genes are unrelated and located in different positions betweem the genes 
encoding the structural proteins.  MHV-1 also offers a safer and less expensive option to 
study SARS-Co disease since MHV-1 can be used under BL2 conditions and is not a 
health hazard to the individuals working with the virus.   
While SARS-CoV is considered as a single entity, there are several studies that 
indicate that SARS-associated coronaviruses also maintain a quasispecies, and the events 
leading up to and during the pandemic were not solely due to the host range changes that 
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can be attributed to the spike protein (64, 141).  During the epidemic different 
quasispecies strains were being generated and had potential effects on patient health and 
survival (144).  Studies have demonstrated the presence of multiple quasispecies of 
SARS-CoV in an individual patient (142, 166).   Our lab has demonstrated a potential 
role for quasispecies in the MHV-1 lung infection (Chapter 4).  We found that infection 
with a virus that had a limited population variance in nsp13 and ns4 resulted in a mild 
infection that only cause limited weight loss.  Whereas infection with a virus who had a 
higher percentage of variants in nsp13 and ns4 had a higher mortality with a lung disease 
that resembled the SARS-CoV like disease reported by De Alburquerque et al (3).   
Research in our lab has shown that MHV-1 is capable of losing virulence in as 
few as three passages.  Two issues have led us to develop a complete reverse genetic 
system: 1) the limitation of targeted recombination to manipulations of the 3’ one third 
of the MHV genome, leaving the nsp13 mutation inaccessible; 2) the larger number of 
tissue culture passages required in preparing the acceptor fMHV-1, and then selecting a 
recombinant virus, allowing more opportunity for cell culture adaptations to arise. Thus, 
we have constructed a Complete Reverse Genetic System for MHV-1.  Several 
Complete Reverse Genetic Systems have already been generated for coronaviruses; they 
include, but are not limited to, SARS-CoV (175), MERS-CoV (134), Infectious 
Bronchitis Virus coronavirus (173), MHV-A59 (176), and MHV-JHM (Susan Weiss, 
personal communication).  We set out, originally, to make our Complete Reverse 
Genetic System compatible with the systems already in place for MHV-A59 and MHV-
JHM to facilitate the generation of chimeras between these strains.  However, because of 
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attributes of the MHV-1 genome we had to use alternative methods to generate our 
system.     
CURRENT PROJECTS 
Generation of an Infectious cDNA Clone 
Early attempts to generate complete reverse genetic systems for coronaviruses 
ended in frustration due to regions of cDNA clones that were unstable in plasmid vectors 
propagated in E. coli (174).  Ultimately this led to three separate strategies to create 
reverse genetic systems:  an in vitro cDNA assembly system, a system employing 
bacterial artificial chromosomes, and a system that assembled a complete cDNA and 
propagated it using a recombinant vaccinia virus vector.  We have elected to utilize the 
in vitro cDNA assembly approach, based on the relative ease of later introducing 
mutations utilizing this system and our labs experience in utilizing this type of system to 
study MHV-A59 replication.   
In the generation of the first coronavirus complete reverse genetic system a 
minimum of 6 plasmids were needed to house the genome (174).  This is because certain 
regions of the genome in ORF1a, specifically the B plasmid region, needed to be broken 
up into separate plasmids in order to avoid bacterial toxicity issues related to the 
sequence.  We employed a similar design.  However, our experiences with the sizable G 
plasmid lead us to utilize a SbfI site present in F to generate two F fragments, F1 and F2 
(Figure 22).  This allowed us to generate smaller cDNA fragments that were less likely 
to contain mutations and plasmids that were easier to manipulate.  
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The MHV-A59 CRGS used a type IIS restriction enzyme, Esp3I or its 
isoschizomer BsmBI, which was added to the ends of the MHV-A59 sequence during 
RT-PCR to cut out the cDNA fragment from its plasmid vector.  Type IIS enzymes cut 
away from their recognition site and produced staggered ends, thus digestion liberates 
cDNAs that only contain MHV genome sequences with staggered ends suitable for 
ligation; the liberated fragments do not carry the recognition sequence for the enzyme.  
The sequence of the MHV-1 genome contained 5 BsmBI sites, making it more 
convenient for us to choose a different type IIS enzyme, BspQI, which is only occurs 
twice within the MHV-1 genome.  Because of this we were not able to make our system 
perfectly compatible with the two MHV complete reverse genetic systems available, 
which utilize BsmBI sites.     
Table 10 shows the genes that are included in each fragment.  The boundaries 
used are not set to individual genes, due to toxicity issues as well as optimal primer and 
restriction site locations.   
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Figure 21.  Outline of the MHV-1 Complete Reverse Genetic System with the 
restriction enzymes flanking each fragment and any mutations made in the 
restriction site. Mutations were made in the restriction sites in order to make the 
MHV-1 system more compatible with other MHV complete reverse genetic systems.  
However, the use of BspQI will require additional steps to make the systems 
genuinely compatible.  MHV-1 native restriction sites are italicized and underlined, 
restriction sites that were engineered in by our lab are italicized, and restriction 
sites that are used in the reverse genetic system are plain lettering.  The BspQI site 
in the 5’UTR (XBspqI) was removed by site directed mutagenesis. 
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Table 10. MHV-1 Complete Reverse Genetic System Plasmid Boundaries 
MHV-1 
genome 
position 
Plasmid Genes Included 
1 to 4869 A  nsp1, nsp2, nsp3 
48644 to 9587 B  nsp3, nsp4 
9585 to 11460 C  nsp4, nsp5, nsp6 
11456 to 
12910 
D nsp6, nsp7, nsp8, nsp9 
12907 to 
15703 
E nsp9, nsp10, nsp11 
15700-22688 F nsp11, nsp12, nsp13, nsp14, nsp15, nsp16, 
ns2,HE 
22685 to End G HE, S, ns4, ns5a, E, M, N 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 117 
 
We maintained the genetic boarders that are present in the MHV-A59 system 
(Table 3).  We also made point mutations so that, in the future, if we wanted to swap 
entire fragments with the MHV-A59 system with modifications to the restriction enzyme 
site to use a Type IIS enzyme that had an equal number of overhanging nucleotides as 
BsmBI.  We did not use BsmBI because there were too many native sites that would 
have had to be mutated, so we used BspQI.  However, BspQI has a three nucleotide 
overhang rather than the four nucleotide overhang created with BsmBI so the two 
enzymes would not create compatible ends.  In the future though, as long as the 
overhang length was four nucleotides so as to be compatible with BsmBI, unique Type 
IIS enzyme sites could be engineered onto the ends of the MHV-1 fragments to make 
them compatible with the MHV-A59 and MHV-JHM systems.  
One challenge with the MHV-1 complete reverse genetic system is that the virus 
used to generate the sequence found in NCBI and used to verify our system is derived 
from a stock in the Weiss lab that does not cause disease in the A/J mouse model of 
SARS-CoV.  To this end we will have to generate mutations based on our whole genome 
sequencing data and compare infection studies with recovered virus to determine what 
sequence generates a virulent virus that can be used as a control.   
FUTURE DIRECTIONS 
Evaluation of the nsp13 and ns4 Mutations Found in Virulent MHV-1 P2.2 
Our analysis of the genomes of virulent and avirulent passages identified two 
mutations that are candidates to affect pathogenicity of MHV-1 in the mouse lung.  We 
will generate three recombinant viruses that differ from the consensus sequence in 
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GenBank: nsp13C/A, ns4G/A, and nsp13/ns4.  Because we cannot determine from the 
genomic sequencing data if the mutations occur individually or in the same virus we will 
have to study the effects of the mutations separately and in combination. 
We believe that the MHV-1 genome submission in GenBank is that of an 
avirulent virus, which was derived from the P3 Weiss MHV-1 which has been tested in 
mice and has shown to not cause penumopathogenesis.  It is also worth noting that 
neither sequence variant is maintained in cell culture over a single passage.  It is possible 
that the nsp13 and ns4 mutations presence at a higher frequency in the virulent virus are 
what contribute to the pneumopaothgenesis of the virulent passage, and this is something 
we plan to test with the complete reverse genetic system.  Because the nsp13 mutation is 
not well maintained even over one passage in cell culture, dropping from 19.1% to 
12.39% we will need to test the variant’s role in infection, as well as it’s stability in cell 
culture.  This can be done by monitoring the mutation’s population in our recombinant 
virus.  Our lab has completed another whole genome sequencing analysis with 
recombinant MHV-A59 P1 and P5 and demonstrated that a single mutation can be 
maintained, and at 100% frequency, over multiple passages in cell culture (167).  So the 
failure of MHV-1 to maintain these mutations is not supportive of the mutations causing 
a gain of function in cell culture.  Though, if these mutations are adversely effecting 
viral replication it is possible that these viruses are what cause the massive immune 
response that lead to the pnuemopathogensis that occurs once the virus is cleared.   
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Evaulation of the Role of ns2 in an MHV-1 Lung Infection 
In MHV ns2 has been shown to be a viral cyclic phosphodiesterase (130).  
Studies done in MHV-JHM show that ns2 has no effect on neuropathogenesis, however 
ns2 has been shown to be very attenuating in the MHV-A59 hepatitis model (130, 183).  
It is unknown as to its role in pathogenesis in the lung, thus we want to examine the role 
of ns2 in the lung.  Using site-directed mutagenesis we generated a single (H46A) and 
double mutations (H46A, H126R) of the ns2 active site histidines, as described 
previously (130).    While the single mutation was proven to be adequate to eliminate 
function and reduce pathogenicity in MHV-A59 infection we wanted to ensure this was 
similar with MHV-1 infection in the lungs.  
DISCUSSION 
 There is still concern that the infectious cDNA method of generating 
recombinant MHV-1 will not be successful in generating a pneumopathogenic virus.  
Our data that shows that MHV-1 cannot be stably maintained as a virulent virus in cell 
culture over multiple passages show that there is more involved in MHV-1 
pneumopathogenesis than is obvious.  While our data seem to show that there may be 
mutations that can be introduced to create a virulent virus, it is also possible that it is the 
presence of a specific quantity of virus subspecies that generates a pneumopathogenic 
infection.  In their paper discussing how quasispecies diversity determines pathogenesis 
Vignuzzi et al do not identify specific mutations that are consistent between a 
neuroinvasive/neurovirulent polio virus and one that is restricted in tissue tropism (156).  
Instead they propose that it is the number of mutations per genome (1.91 vs 0.31, 
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neuropathogenic vs restricted virus) that aid in neuroinvasiveness and pathogenesis, not 
specific mutations.  However, their method of quantifying quasispecies relied on picking 
24 virus isolates that were amplified, and the viral RNA was extracted and purified for 
RT-PCR and direct sequencing.  This method will only identify dominant mutations that 
are present in a population, so it is possible that the actual quasispecies variability is 
much larger than what is presented in the paper.  While this method is effective for polio 
virus, it is not quite a viable method for coronaviruses, given the difference in genome 
size that would need to be sequenced.   
The ability to generate a population that is sufficient in number and type of 
subspecies may not be possible with the infectious cDNA method.  This method cannot 
control sequence diversity to a fine degree if we do not know what specific elements 
need to be incorporated to generate a pneumopathogenic virus infection.  So while the 
experiments mentioned above might be helpful in determining if specific mutations play 
a role in quasispecies diversity in an MHV-1 infection, they will not be productive if the 
requirement for pneumopathogenicity is a quasispecies quantity, not specific mutations 
that must be present at certain population percentages.  In that case determining the role 
of ns2 in pneumovirulence would be impossible if one cannot generate a pneumovirulent 
virus.   
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CHAPTER VI 
CONCLUSION 
 
Since the emergence of SARS-CoV in 2003 there has been renewed interest in 
human coronavirus disease.  The SARS-CoV is classified as BSL3 select agent; 
experiments with SARS-CoV are potentially dangerous to staff and are expensive for the 
researcher.  SARS-CoV disease also has limited reproduction in animal models, or 
requires an adapted virus to generate a SARS-CoV like clinical disease (78, 82, 92, 100).  
It has been demonstrated that MHV-1 produces a disease in 6 week old female A/J mice 
that is clinically similar to SARS-CoV infection in elderly humans (3).  In order to 
further study the potential of a MHV-1 model of SARS-CoV we first developed a 
targeted recombination system to generate recombinant MHV-1 viruses with mutations 
at the 3’ end of the genome.  This system was similar to the system designed by Kuo et 
al, utilizing a recombinant MHV-A59 virus (fMHV) expressing the ectodomain of the 
spike protein from Feline Infectious Peritonitis Virus  to identify recombination events 
between the recombinant fMHV and Donor RNA that coded for the native MHV-A59 
spike (75).  We created fMHV-1 as the acceptor virus using in vitro transcribed Donor 
RNA that contained MHV-1 sequences that extended from HE codon 28 to the 3’ end of 
the genome.  The Donor RNA was transfected into feline cells that were infected with 
fMHV-1 and the infected/transfected cells were overlaid onto murine DBT cells.  Over 
three days the mixed cell culture was observed for signs of infection, including syncytia 
and cell death.  Recombinant viruses that resulted from the targeted recombination 
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protocol were expanded once in murine cells, plaque purified, expanded in DBTs, and 
sequenced to confirm the presence of MHV-1.   
This system was used to successfully generate multiple recombinant viruses, 
many that were not significantly different from MHV-1 in in vitro analyses.  There were 
some recombinant viruses that were generated that appeared to have a growth deficiency 
compared to MHV-1, however because all recombinants had multiple independent 
isolates we always had at least one recombinant isolate that was not significantly 
different than MHV-1 in cell culture.  Upon infection of A/J mice with any the 
recombinant viruses generated, none demonstrated a pathogenicity that was similar to 
MHV-1.  All viruses tested had a higher LD50 than MHV-1.  The LD50 of our 
recombinant viruses was too high to calculate the actual value because of the amount of 
virus that would be required to do successful infections was so great that we were not 
confident we could generate stocks with a high enough titer to do successful infections.  
The recombinant viruses only caused a minor illness as evidenced by limited weight 
loss, compared to controls, and animals also showed less lung damage, compared the 
controls, as evaluated by the oxygen saturation levels using the Mouse Ox Pulse 
Oximeter.   
 During the analysis of our recombinant viruses we noticed that our lab stock of 
MHV-1 dramatically lost pathogenicity in A/J mice with passage in cell culture.  After 
multiple dose and animal studies we resolved that the loss of pathogenicity in our MHV-
1 stock was due to some type of cell culture adaptation.  In order to evaluate the cause of 
the loss of virulence we did Next-Generation sequencing on an avirulent and a virulent 
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passage of MHV-1 (P3 and P2, respectively).  We did not find any dominant mutations 
that deviated from the MHV-1 sequence as it appears in NCBI (FJ647223.1, noting that 
this sequence is missing bases at the 5’ end that can be found in EF682499).  Upon 
analysis of these sequences looking for variant populations we found that each passage, 
virulent and avirulent, had a population variant in common as well as an independent 
population variant that was unique to each, when compared to the NCBI reference 
sequence.  Both populations contained a C17015A mutation that created an A237D 
mutation in the nsp13 gene.  The avirulent population had this mutation in ~12% of the 
population and the virulent population had this mutation in ~19% of the population.  
This mutation appears to effect a helical structure, but does not affect a known active site 
contained in nsp13 (63).  However, the spacer region in an equivalent protein in 
arterivirus, ns10, has been characterized and researchers have shown that mutations in 
this region tend to be detrimental to the function of the protein in terms of generation of 
discontinuous mRNA synthesis either resulting in non-viable virus or temperature 
sensitive mutants (29).  Why the virulent virus would select for a potentially detrimental 
mutation is uncertain, though the higher percentage of viruses with a fully functional 
nsp13 may be contributing to virulence.  Or it is possible that the mutation is generating 
temperature sensitive mutations that are beneficial to the viral population in the 
respiratory tract. The avirulent virus also contained the A23791G silent mutation in a 
region of the HE gene that is after the stop codons that render HE a psuedogene in 
MHV-1.  The role of this mutation is unknown since it is non-coding and also in a 
pesudogene. The virulent virus passage has a C28454G mutation that is present in ns4 
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that creates an A133T mutation.  This coding mutation interrupts a helical structure that 
is present at the carboxy end of the protein.  However, the role and function of ns4 is not 
well characterized in MHV-1, so this mutation is of particular interest for future study.  
When we looked for these sequence variations by subcloning and Sanger sequencing we 
were unable to find these specific variants.   
 Ultimately the rapid generation of non-pathogenic MHV-1 in cell culture 
implies that the targeted recombination system will never be successfully adapted to the 
MHV-1 model of SARS-CoV disease.  The nature of the targeted recombination system 
involves multiple passages in cell culture, more passages than were used to generate the 
stock MHV-1.  Because of this our lab’s efforts focused more on our generation of a 
reverse genetic system that we could utilize that would require less time being passaged 
in cell culture.  
 We have established a potential role for quasispecies in the MHV-1 virulence 
in lungs.  The population variances between virulent and avirulent passages demonstrate 
that there is a need for a certain percentage of nsp13 mutants in a virulent virus.  There is 
also a potential role for ns4 mutants in the generation of a virulent and 
pneumopathogenic MHV-1 infection.  The exact role of these variants cannot be known 
because we do not know the sequence of a pneumovirulent MHV-1.  We have 
established that the sequence present in NCBI is not sufficient to cause 
pneumopathogenic in five to seven week old female A/J mice.  The question that 
remains is if pneumovirulence is a factor of specific variants or the presence of 
quasispecies.  The finding of a potential role for quasispecies in the MHV-1 infection of 
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the lung is consistent with the finding of quasispecies of SARS-CoV in human patients 
and, potentially, gives support to the hypothesis that quasispecies can have an effect on 
pathogenicity and overall clinical severity of a SARS-CoV infection (144, 153, 166).   
 The generation of infectious cDNA from multiple cDNA fragments has been 
used successfully for many other coronaviruses (5–9, personal communication with 
Weiss lab).  We generated our cDNA fragments by size and location similarly to the 
MHV-A59 system (176).  We used type IIS restriction enzyme sites flanking most of the 
fragments, where unique native sites were not found, to liberate cDNA containing only 
MHV-1 sequence, similarly to what was done by Yount, et al.  Single base mutations 
were introduced at some of the overhangs in order to facilitate the potential that later the 
fragments could be used interchangeably with other MHV reverse genetic systems, with 
a few other modifications.  We elected not to to use the BsmBI site that is used in the 
MHV-A59 system for two reasons: first there is a BsmBI site in a region of the 3’ UTR 
that is termed “the octomer” (47).  This site is highly conserved between many members 
of the coronavirus family, and had been shown to effect virus growth in cell culture, thus 
we were reluctant to mutate it in the G fragment.  Second, there are multiple other 
BsmBI sites in other fragments that would have required mutations to eliminate, and 
after the failures with the recombinant viruses that were generated with the targeted 
recombination system we wanted to introduce as few artificial mutations as possible.  
We chose to use the BspQI site, which did have a native site in the 5’ UTR that we 
believed could be manipulated with little concern as it had no known associated 
structural function (18, 67).   
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 The original cDNA fragments were generated to match the MHV-1 genome in 
NCBI.  However, with our data that indicates that the NCBI sequence is not sufficient to 
create lung disease in A/J mice we are also generating viruses that contain the mutations 
in nsp13 and ns4 found in the virulent passage.  We hope to test these mutations 
individually and in concert to determine which virus is able to generate lethal severe 
MHV-1 induced pneumonitis.  We also plan to identify the role, if any, of ns2 in the 
lungs.  Previous research has shown that ns2, a viral cyclic phosphodiesterase, has been 
shown to play an important role in pathogenesis of MHV-A59 in the liver, but is not 
important in the infection and pathogenesis of MHV-JHM in the brain (130, 183).  
Personal communication with the Weiss lab indicates that the infection and replication 
of MHV-A59 in alveolar macrophages (a site of MHV-1 infection) does not rely on a 
functioning ns2 protein. Its importance to viral replication in other cells found in the 
lung is unknown.  
 The use of reverse genetic systems is an invaluable tool in the study of virus 
gene function in vitro and in vivo.  We have demonstrated that not all reverse genetic 
systems are viable options for the evaluation of gene functions due to the nature of the 
protocol.  The targeted recombination system has proven to be a tool that is not usable in 
the evaluation of MHV-1 as a model for SARS-CoV because during the generation of 
the recombinant virus there is a loss of virulence through multiple passage in cell 
culture.  Targeted recombination can be used to evaluate gene function in vitro, but will 
not be successful in in vivo animal experiments because virulent viruses are difficult to 
generate with this system.  To that end MHV-1 recombinant viruses will have to be 
 127 
 
generated using a system that does not require extended passage time in cell culture.  
The infectious cDNA clone generated from cDNA fragments is one option, though there 
are other methods that can be used to generate viable virus with limited passage in cell 
culture (146, 173).   
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APPENDIX 
 
Analysis of nsp13 population variant in lung and cell culture. 
Viral RNA was extracted from day 3 post infection mouse lung homogenate, 
P3.2.1, and P4.2.1.  The nsp13 region of interest was reverse transcribed and PCR 
amplified.  The PCR product was subcloned into PGEM-T Easy.  Colonies were 
sequenced and the variant population was analyzed.  By this method we are, currently,  
unable to find our original C17040A variant from the whole genome sequencing.  This is 
likely due to the fact that colony screening is less sensitive in quantifying population 
variants.   Our screening did not detect the C17040A variant, demonstrating that this 
variant is not well conserved over passage in tissue culture nor in infection in the A/J 
mouse. 
 
Table A 1. Passage population of nsp13 C17040A variants from different sources 
Passage ID Cell type Variant population Percent frequency 
P2.2 Lung homogenate 0/14 0% 
P3.2.1 DBT 0/17 0% 
P 4.2.1 DBT 0/21 0% 
P 2.2 DBT 456/2387 19.1% 
P3.3 DBT 2,085/16,842 12.3% 
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Analysis of ns4 variant population in lung and cell culture 
 Viral RNA was extracted from a P3.2.1 and P4.2.1 and the ns4 region of interest 
was reverse transcribed and PCR amplified.  The PCR product was subcloned into 
PGEM-T Easy.  Colonies were sequenced and the variant population was analyzed.  By 
this method we were unable to find our original G28479A variant from the whole 
genome sequencing.  This is likely due to the fact that colony screening is less sensitive 
in quantifying population variants.  Especially since the highest population variant of the 
ns4 G28479A was 10% in P2.2, and was reduced to 2% in P3.2, it was unlikely that we 
would find the variant by colony screening.  This does confirm that the ns4 variant is not 
maintained in tissue culture passage.   
 
Table A 2. Passage population of ns4 G28479A variants 
Passage ID Cell Type Variant Population Percent Frequency 
P3.2.1 DBT 0/22 0% 
P4.2.1 DBT 0/21 0% 
P2.2 DBT 445/4087 10.89% 
P3.3 DBT 434/18065 2.4% 
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Conservation of nsp13 variant in group 1 betacoronaviruses 
Because the nsp13 G17040A variant causes a coding difference we decided to 
evaluate this amino acid change in the context of other group 1 betacoronaviruses.  
Using ClustalW2 we compared the nsp13 regions of the virulent MHV-1, MHV-A59, 
MHV-JHM, Human Coronavirus HKU1 (NC_006577.2), and Human Coronavirus 
OC43 (NP_937951.1).  The alignment (Figure A1) shows that the nsp13 A237D amino 
acid change present in the virulent MHV-1 is not present in any other group 1 
betacoronavirus.  This amino acid change also creaks up a highly conserved region of 12 
consecutive amino acids.   
 
MHV-JHMnsp13       SVGACVVCSSQTSLRCGSCIRKPLLCCKCAYDHVMSTDHKYVLSVSPYVCNSPGCDVNDV 60 
MHV-A59nsp13       SVGACVVCSSQTSLRCGSCIRKPLLCCKCAYDHVMSTDHKYVLSVSPYVCNSPGCDVNDV 60 
MHV-1nsp13V        SVGACVVCSSQTSLRCGSCIRKPLLCCKCAYDHVMSTDHKYVLSVSPYVCNSPGCDVNDV 60 
HOC43nsp13         SVGACVVCSSQTSLRCGSCIRKPLLCCKCCYDHVMATDHKYVLSVSPYVCNAPGCDVNDV 60 
HCoVHKU1nsp13      SVGACVVCSSQTSLRCGSCIRKPLLCCKCCYDHVMATNHKYVLSVSPYVCNAPNCDVSDV 60 
                   *****************************.*****:*:*************:*.***.** 
 
MHV-JHMnsp13       TKLYLGGMSYYCEAHKPQYSFKLVMNGMVFGLYKQSCTGSPYIEDFNKIASCKWTEVDDY 120 
MHV-A59nsp13       TKLYLGGMSYYCEDHKPQYSFKLVMNGMVFGLYKQSCTGSPYIEDFNKIASCKWTEVDDY 120 
MHV-1nsp13V        TKLYLGGMSYYCEDHKPQYSFKLVMNGMVFGLYKQSCTGSPYIEDFNKIASCKWTEVDDY 120 
HOC43nsp13         TKLYLGGMSYYCEDHKPQYSFKLVMNGLVFGLYKQSCTGSPYIDDFNRIASCKWTDVDDY 120 
HCoVHKU1nsp13      TKLYLGGMSYYCENHKPHYSFKLVMNGMVFGLYKQSCTGSPYIDDFNKIASCKWTEVDDY 120 
                   ************* ***:*********:***************:***:*******:**** 
 
MHV-JHMnsp13       VLANECTERLKLFAAETQKATEEAFKQCYASATIREIVSDRELILSWEIGKVRPPLNKNY 180 
MHV-A59nsp13       VLANECTERLKLFAAETQKATEEAFKQCYASATIREIVSDRELILSWEIGKVRPPLNKNY 180 
MHV-1nsp13V        VLANECTERLKLFAAETQKATEEAFKQCYASATIREIVSDRELILFWEIGKVRPPLNKNY 180 
HOC43nsp13         ILANECTERLKLFAAETQKATEEAFKQSYASATIQEIVSERELILSWEIGKVKPPLNKNY 180 
HCoVHKU1nsp13      VLANECIERLKLFAAETQKATEEAFKQSYASATIQEIVSDREVILCWETGKVKPPLNKNY 180 
                   :***** ********************.******:****:**:** ** ***:******* 
 
MHV-JHMnsp13       VFTGYHFTNNGKTVLGEYVFDKSELTNGVYYRATTTYKLSVGDVFILTSHAVSSLSAPTL 240 
MHV-A59nsp13       VFTGYHFTNNGKTVLGEYVFDKSELTNGVYYRATTTYKLSVGDVFILTSHAVSSLSAPTL 240 
MHV-1nsp13V        VFTGYHFTSNGKTVLGEYVFDKSELTNGVYYRATTTYKLSVGDVFILTSHAVSSLSDPTL 240 
HOC43nsp13         VFTGYHFTKNGKTVLGEYVFDKSELTNGVYYRATTTYKLSVGDVFVLTSHSVANLSAPTL 240 
HCoVHKU1nsp13      VFTGYHFTSTGKTVLGEYVFDKSELTNGVYYRATTTYKLSIGDVFVLTSHSVASLSAPTL 240 
                   ********..******************************:****:****:*:.** *** 
Figure A 1. ClustalW2 alignement of a fragment of the nsp13 proteins of select 
group 1 betacoroanviruses.  The highlighted region shows inidicated the A237D 
amino acid change in the virulent strain of MHV-1.  This alignement shows that the 
amino acid change is in a region that is conserved in selected group 1 
beatcoronaviruses.   
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Conservation of ns4 variant in group 1 betacoronaviruses 
 Because the ns4 G28479A variant causes a coding difference we decided to 
evaluate this amino acid change in the context of other group 1 betacoronaviruses.  
Using ClustalW2 we compared the ns4 regions of the virulent MHV-1, MHV-A59, 
MHV-JHM, Human Coronavirus HKU1 (NC_006577.2), and Human Coronavirus 
OC43 (NP_937951.1).  This alignment (Figure A2) shows that the region at the carboxy 
terminus is not well conserved among group 1 betacoronaviruses.  Only MHV-1 and 
MHV-JHM share a similar carboxy terminus end, so we cannot make comparisons about 
the potential role of this amino acid change based on this information.  
 
MHV-1ns4V        ---------------------------------MAIIGPKTTIAAVFIGPFIVACMLGIG 27 
MHV-JHMns4       ---------------------------------MALIGPKTTIAAVFIGPFLVACMLGIG 27 
MHV-A59ns4       MRIDYHSLSWKDRKSKQFIAFSLLPGPVRGSHSYGRVGPKATLAAVFIGPFIVACMLGIG 60 
HCoVHKU1ns4      ---------------------------------MDVWRPSYTHSLVIR---------EFG 18 
HOC43ns4         ---------------------------------MDIWRPEKKYLRYIN---------GFN 18 
                                                       *. .    :           :. 
 
MHV-1ns4V        LVYLLQLQVQIFHVNDTIRVTGKPATVSYTISTPVTPSATTLDGTTYTLIRPTSSYTRVH 87 
MHV-JHMns4       LVYLLQLQVQIFHVKDTIRVTGKPATVSYTTSTPVTPVATTLDGTTYTLIRPTSSYTRVY 87 
MHV-A59ns4       LVYLLQLQVQIFHVKDTIRVTGKPATVSYTTSTPVTPSATTLDGTTYTLIRPTSSYTRVY 120 
HCoVHKU1ns4      VTNLEDLCLKYNYCQPIVGYCIVPLNVWCRKFGKFA--------SHFTLRSHDISHS-NN 69 
HOC43ns4         VSELEDACFKFNYQFPKVGYCRVPSHAWCRNQGRFC--------ATFTLYGKSKHYD-KY 69 
                 :  * :  .:  :    :     *  .       .         : :**      :     
 
MHV-1ns4V        LGSPRGFDTSTFGPKTLDYTTSSKPHLNSGRPYTLRHLPKYMTPPTIWRFGM 139 
MHV-JHMns4       LGSSRGFDTSTFGPKTLDYITSSKPHLNSGRPYTLRHLPKYMTPPATWRFGL 139 
MHV-A59ns4       LGTPRGFDYSTFGPKTLDYVTNLNLILILVVHILLRHCP-----------GI 161 
HCoVHKU1ns4      FGVVTSFT--TYGNTVSEAVSRLVESASEFIVWRAEALNKYG---------- 109 
HOC43ns4         FGVINGFT--AFANTVEDAVNKLVFLAVDFITWRRQELNVYG---------- 109 
                 :*   .*   ::. .. :  .              .                 
Figure A 2.  ClustalW2 alignement of ns4 proteins of select group 1 
betacoroanviruses.  The ns4 proteins from each virus were aligned using ClustalW2 
and show that the A133T amino acid change (highlighted region) caused by the 
variant population in the virulent MHV-1 is not conserved among selected group 1 
betacoronaviruses.   
